본문 바로가기
KERD
논문KCI 등재

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Korean Liver Cancer Association (KLCA)|National Cancer Center (NCC) Korea
대한간학회 (The korean Association for the Study of the Liver)|2022.10|Clinical and Molecular Hepatology|제28권 제4호|pp. 583-705

3

조회

0

다운로드

61

인용

0

참고문헌

키워드

ManagementGuidelinesDiagnosisHepatocellular carcinoma

초록

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.

참고문헌 (1028)

  1. Guyatt GH, "GRADE : an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
  2. Guyatt GH, "What is"quality of evidence"and why is it important to clinicians?", BMJ, 336, pp.995~998 (2008)
  3. Guyatt GH, "Going from evidence to recommendations", BMJ, 336, pp.1049~1051 (2008)
  4. Schünemann HJ, "Grading quality of evidence and strength of recommendations for diagnostic tests and strategies", BMJ, 336, pp.1106~1110 (2008)
  5. Brouwers MC, "Development of the AGREE II, part 1 : performance, usefulness and areas for improvement", CMAJ, 182, pp.1045~1052 (2010)
  6. Brouwers MC, "Development of the AGREE II, part 2 : assessment of validity of items and tools to support application", CMAJ, 182, pp.E472~E478 (2010)
  7. Lozano R, "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010 : a systematic analysis for the global burden of disease study 2010", Lancet, 380, pp.2095~2128 (2012)
  8. GBD 2013 Mortality, "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013 : a systematic analysis for the global burden of disease study 2013", Lancet, 385, pp.117~171 (2015)
  9. 이광식, "Economic Burden of Cancer in Korea during 2000-2010", Cancer Research and Treatment, 47(3), pp.387~398 (2015), 대한암학회[DOI]
  10. 김영애, "Socioeconomic Burden of Cancer in Korea from 2011 to 2015", Cancer Research and Treatment, 52(3), pp.896~906 (2020), 대한암학회[DOI]
  11. Annual report of Korean central cancer registry (2019), "Korean Central Cancer Registry", Korea Central Cancer Registry, ~ (2021)
  12. 전영은, "Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry", Journal of Liver Cancer, 20(2), pp.135~147 (2020), 대한간암학회[DOI]
  13. Choi SI, "Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea : changes in 16-years cohorts", PLoS One, 17, pp.e0265668~ (2022)
  14. Annual report of Korean central cancer registry (2015), "Korean Central Cancer Registry", Korea Central Cancer Registry, ~ (2017)
  15. Fujiwara N, "Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine", J Hepatol, 68, pp.526~549 (2018)
  16. Chang MH, "Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees : a 20-year follow-up study", J Natl Cancer Inst, 101, pp.1348~1155 (2009)
  17. World Health Organization(WHO), "Hepatitis B vaccines : WHO position paper", WHO, ~ (2017)
  18. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
  19. Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
  20. Park Hana, "Systematic Review with Meta-Analysis: Low-Level Alcohol Consumption and the Risk of Liver Cancer", Gut and Liver, 14(6), pp.792~807 (2020), 거트앤리버 소화기연관학회협의회[DOI]
  21. Marrero JA, "Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma", J Hepatol, 42, pp.218~224 (2005)
  22. El-Serag HB, "Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma", Gastroenterology, 126, pp.460~468 (2004)
  23. Lee YB, "Association of metabolic risk factors with risks of cancer and allcause mortality in patients with chronic hepatitis B", Hepatology, 73, pp.2266~2277 (2021)
  24. Singh S, "Statins are associated with a reduced risk of hepatocellular cancer : a systematic review and meta-analysis", Gastroenterology, 144, pp.323~332 (2013)
  25. Simon TG, "Lipophilic statins and risk for hepatocellular carcinoma and death in patients with chronic viral hepatitis : results from a nationwide swedish population", Ann Intern Med, 171, pp.318~327 (2019)
  26. Tran KT, "Statin use and risk of liver cancer : evidence from two population-based studies", Int J Cancer, 146, pp.1250~1260 (2020)
  27. Kim G, "Statin use and the risk of hepatocellular carcinoma in patients at high risk : a nationwide nested case-control study", J Hepatol, 68, pp.476~484 (2018)
  28. Goh MJ, "Statin use and the risk of hepatocellular carcinoma in patients with chronic hepatitis B", Hepatology, 71, pp.2023~2032 (2020)
  29. Islam MM, "Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies", Cancers(Basel), 12, pp.671~ (2020)
  30. Wong YJ, "Efficacy and safety of statin for hepatocellular carcinoma prevention among chronic liver disease patients : a systematic review and metaanalysis", J Clin Gastroenterol, 55, pp.615~623 (2021)
  31. Choi J, "Statins and metformin for chemoprevention of hepatocellular carcinoma", Clin Liver Dis(Hoboken), 8, pp.48~52 (2016)
  32. Chen HP, "Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner : population-based and in vitro studies", Gut, 62, pp.606~615 (2013)
  33. Sahasrabuddhe VV, "Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma", J Natl Cancer Inst, 104, pp.1808~1814 (2012)
  34. Simon TG, "Association between aspirin use and risk of hepatocellular carcinoma", JAMA Oncol, 4, pp.1683~1690 (2018)
  35. Simon TG, "Association of aspirin with hepatocellular carcinoma and liver-related mortality", N Engl J Med, 382, pp.1018~1028 (2020)
  36. Lee M, "Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment", Hepatology, 66, pp.1556~1569 (2017)
  37. Li X, "Aspirin use and the incidence of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis of cohort studies", Front Med(Lausanne), 7, pp.569759~ (2021)
  38. Tan RZH, "Systematic review with meta-analysis : the effects of non-steroidal antiinflammatory drugs and anti-platelet therapy on the incidence and recurrence of hepatocellular carcinoma", Aliment Pharmacol Ther, 54, pp.356~367 (2021)
  39. Wang S, "Association of aspirin therapy with risk of hepatocellular carcinoma : a systematic review and dose-response analysis of cohort studies with 2. 5 million participants", Pharmacol Res, 151, pp.104585~ (2020)
  40. Jang H, "Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis", Hepatology, 76, pp.492~501 (2022)
  41. Bravi F, "Coffee reduces risk for hepatocellular carcinoma : an updated metaanalysis", Clin Gastroenterol Hepatol, 11, pp.1413~1421 (2013)
  42. Inoue M, "Influence of coffee drinking on subsequent risk of hepatocellular carcinoma : a prospective study in Japan", J Natl Cancer Inst, 97, pp.293~300 (2005)
  43. Gelatti U, "Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology : a casecontrol study", J Hepatol, 42, pp.528~534 (2005)
  44. Setiawan VW, "Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort", Gastroenterology, 148, pp.118~125 (2015)[DOI]
  45. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
  46. The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", Clinical and Molecular Hepatology, 24(3), pp.169~229 (2018), 대한간학회
  47. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
  48. Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
  49. Kim WR, "Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B", Cancer, 121, pp.3631~3638 (2015)
  50. Colombo M, "Role of antiviral treatment for HCC prevention", Best Pract Res Clin Gastroenterol, 28, pp.771~781 (2014)
  51. Choi J, "Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B : a Korean nationwide cohort study", JAMA Oncol, 5, pp.30~36 (2019)
  52. Kim SU, "A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea", J Hepatol, 71, pp.456~464 (2019)
  53. Lee SW, "Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea : a large-scale, propensity score analysis", Gut, 69, pp.1301~1308 (2020)
  54. Choi HeeKyoung, "Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea", Journal of Korean Medical Science, 36(14), pp.1~10 (2021), 대한의학회[DOI]
  55. Dave S, "Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B : a systematic review and meta-analysis", Hepatology, 73, pp.68~78 (2021)
  56. Tseng CH, "Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B : a systematic review and metaanalysis", Lancet Gastroenterol Hepatol, 5, pp.1039~1052 (2020)
  57. Lee HW, "Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B", J Viral Hepat, 28, pp.1570~1578 (2021)
  58. Lee HW, "Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B", Hepatol Int, 15, pp.1083~1092 (2021)
  59. Li M, "Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B : a critical systematic review and meta-analysis", Hepatol Int, 14, pp.105~114 (2020)
  60. Sung Won Lee, "Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(3), pp.402~412 (2021), 대한간학회[DOI]
  61. Friberg S, "On the growth rates of human malignant tumors : implications for medical decision making", J Surg Oncol, 65, pp.284~297 (1997)
  62. Lim YS, "Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine", Gastroenterology, 147, pp.152~161 (2014)
  63. Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : a systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
  64. Choi J, "Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population", Hepatology, 66, pp.1454~1463 (2017)
  65. Singal AG, "A sustained viral response is associated with reduced liverrelated morbidity and mortality in patients with hepatitis C virus", Clin Gastroenterol Hepatol, 8, pp.280~288 (2010)[DOI]
  66. Morgan RL, "Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma : a meta-analysis of observational studies", Ann Intern Med, 158, pp.329~337 (2013)
  67. Carrat F, "Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment : a prospective cohort study", Lancet, 393, pp.1453~1464 (2019)
  68. Calvaruso V, "Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents", Gastroenterology, 155, pp.411~421 (2018)
  69. Mendizabal M, "Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents", Clin Gastroenterol Hepatol, 18, pp.2554~2563 (2020)
  70. Waziry R, "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy : a systematic review, meta-analyses, and meta-regression", J Hepatol, 67, pp.1204~1212 (2017)
  71. Delgado Martínez C, "Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations", Ann Hepatol, 21, pp.100225~ (2021)
  72. Yin J, "Effect of antiviral treatment with nucleotide", nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma : a two-stage longitudinal clinical study, 2013, pp.31, 3647~3655
  73. Wong JS, "Meta-analysis : the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma", Aliment Pharmacol Ther, 33, pp.1104~1112 (2011)
  74. Miao RY, "Postoperative adjuvant antiviral therapy for hepatitis B", C virusrelated hepatocellular carcinoma : a meta-analysis, 2010, pp.16, 2931~2942
  75. Chen XX, "The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection : a systematic review and meta-analysis", Onco Targets Ther, 10, pp.5363~5375 (2017)
  76. Choi J, "Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection", Hepatology, 73, pp.661~673 (2021)
  77. Huang G, "Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load", Ann Surg Oncol, 20, pp.1482~1490 (2013)
  78. Lee JH, "The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma", Eur J Intern Med, 89, pp.48~55 (2021)
  79. Singal AK, "Meta-analysis : interferon improves outcomes following ablation or resection of hepatocellular carcinoma", Aliment Pharmacol Ther, 32, pp.851~858 (2010)
  80. Reig M, "Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy", J Hepatol, 65, pp.719~726 (2016)
  81. Conti F, "Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals", J Hepatol, 65, pp.727~733 (2016)
  82. Reig M, "Liver cancer emergence associated with antiviral treatment : an immune surveillance failure?", Semin Liver Dis, 37, pp.109~118 (2017)
  83. Saraiya N, "Systematic review with meta-analysis : recurrence of hepatocellular carcinoma following direct-acting antiviral therapy", Aliment Pharmacol Ther, 48, pp.127~137 (2018)
  84. ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, "Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts", Journal of Hepatology, 65(4), pp.734~740 (2016), Elsevier BV[DOI]
  85. Cabibbo G, "Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCVcirrhotic patients", J Hepatol, 71, pp.265~273 (2019)
  86. Sahakyan Y, "Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C : systematic review and meta-analysis", J Viral Hepat, 28, pp.739~754 (2021)
  87. Pang Q, "The effects of nonsteroidal anti-inflammatory drugs in the incident and recurrent risk of hepatocellular carcinoma : a meta-analysis", Onco Targets Ther, 10, pp.4645~4656 (2017)
  88. Li X, "Statin use and the prognosis of patients with hepatocellular carcinoma : a meta-analysis", Biosci Rep (2020)
  89. Nishio T, "Impact of statin use on the prognosis of patients with hepatocellular carcinoma undergoing liver resection : a subgroup analysis of patients without chronic hepatitis viral infection", Surgery, 163, pp.264~269 (2018)
  90. Cho Y, "Statin use is associated with decreased hepatocellular carcinoma recurrence in liver transplant patients", Sci Rep, 9, pp.1467~ (2019)
  91. Lee HL, "Anticancer effect of statins in patients undergoing liver transplantation for hepatocellular carcinoma", Liver Transpl, 28, pp.397~406 (2022)
  92. Chen JG, "Screening for liver cancer : results of a randomised controlled trial in Qidong, China", J Med Screen, 10, pp.204~209 (2003)
  93. Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma", J Cancer Res Clin Oncol, 130, pp.417~422 (2004)
  94. Singal A, "Meta-analysis : surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis", Aliment Pharmacol Ther, 30, pp.37~47 (2009)
  95. Zhao C, "Hepatocellular carcinoma screening and surveillance : practice guidelines and real-life practice", J Clin Gastroenterol, 50, pp.120~133 (2016)
  96. Sangiovanni A, "Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance", Gastroenterology, 126, pp.1005~1014 (2004)
  97. Santi V, "Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival", J Hepatol, 53, pp.291~297 (2010)
  98. Kim HD, "Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival", Gastroenterology, 148, pp.1371~1382 (2015)
  99. Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a meta-analysis", Gastroenterology, 154, pp.1706~1718 (2018)
  100. Parikh ND, "Cost-effectiveness of hepatocellular carcinoma surveillance : an assessment of benefits and harms", Am J Gastroenterol, 115, pp.1642~1649 (2020)
  101. Shim CW, "Noncirrhotic hepatocellular carcinoma : etiology and occult hepatitis B virus infection in a hepatitis B virus-endemic area", Therap Adv Gastroenterol, 10, pp.529~536 (2017)
  102. Hartke J, "The diagnosis and treatment of hepatocellular carcinoma", Semin Diagn Pathol, 34, pp.153~159 (2017)
  103. Dulku G, "The role of imaging in the surveillance and diagnosis of hepatocellular cancer", J Med Imaging Radiat Oncol, 61, pp.171~179 (2017)
  104. Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class a cirrhosis", Am J Med, 101, pp.422~434 (1996)
  105. Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
  106. Zanetto A, "Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals", Liver Transpl, 23, pp.1103~1112 (2017)
  107. Ogata F, "Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis C virus genotype 1-related chronic liver disease", Oncology, 93, pp.92~98 (2017)
  108. Calleja JL, "Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection : results from a spanish real-world cohort", J Hepatol, 66, pp.1138~1148 (2017)
  109. Loomba R, "AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease : expert review", Gastroenterology, 158, pp.1822~1830 (2020)
  110. Chou R, "Imaging techniques for the diagnosis of hepatocellular carcinoma : a systematic review and meta-analysis", Ann Intern Med, 162, pp.697~711 (2015)
  111. Singal AG, "Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial : where did surveillance fail?", Am J Gastroenterol, 108, pp.425~432 (2013)
  112. Colli A, "Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma : a systematic review", Am J Gastroenterol, 101, pp.513~523 (2006)
  113. Aghoram R, "Alpha-foetoprotein and", or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B, 2012, ~
  114. European Association For The Study Of The Liver, "EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
  115. Kokudo N, "Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan : the J-HCC guidelines", J Gastroenterol, 44(19), pp.119~121 (2009)
  116. 한국 간 암 스터디그룹, "2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Gut and Liver, 9(3), pp.267~317 (2015), 거트앤리버 소화기연관학회협의회
  117. Korean Liver Cancer Study Group and National Cancer Center, "Practice guidelines for management of hepatocellular carcinoma 2009", Korean J Hepatol, 15, pp.391~423 (2009)
  118. Santagostino E, "A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus", Blood, 102, pp.78~82 (2003)
  119. Trinchet JC, "Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis : a randomized trial comparing 3-and 6-month periodicities", Hepatology, 54, pp.1987~1997 (2011)
  120. Wang JH, "Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis : a randomized study in community", Am J Gastroenterol, 108, pp.416~424 (2013)
  121. Andersson KL, "Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 6, pp.1418~1424 (2008)
  122. Barbara L, "Natural history of small untreated hepatocellular carcinoma in cirrhosis : a multivariate analysis of prognostic factors of tumor growth rate and patient survival", Hepatology, 16, pp.132~137 (1992)
  123. Sheu JC, "Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications", Gastroenterology, 89, pp.259~266 (1985)
  124. Tanaka H, "Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrastenhanced ultrasonography", Hepatol Res, 42, pp.376~384 (2012)
  125. Pocha C, "Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography--a randomised study", Aliment Pharmacol Ther, 38, pp.303~312 (2013)
  126. Gupta P, "Abbreviated MRI for hepatocellular carcinoma screening : a systematic review and meta-analysis", J Hepatol, 75, pp.108~119 (2021)
  127. European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
  128. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
  129. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
  130. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : the Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
  131. Moctezuma-Velázquez C, "Non-invasive imaging criteria for the diagnosis of hepatocellular carcinoma in non-cirrhotic patients with chronic hepatitis B", JHEP Rep, 3, pp.100364~ (2021)
  132. Lewis S, "Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis", AJR Am J Roentgenol, 200, pp.W610~W616 (2013)
  133. Kim SE, "Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area", Liver Int, 31, pp.1468~1476 (2011)
  134. Van Wettere M, "Low specificity of washout to diagnose hepatocellular carcinoma in nodules showing arterial hyperenhancement in patients with budd-chiari syndrome", J Hepatol, 70, pp.1123~1132 (2019)
  135. Wells ML, "Benign nodules in post-Fontan livers can show imaging features considered diagnostic for hepatocellular carcinoma", Abdom Radiol(NY), 42, pp.2623~2631 (2017)
  136. Roberts LR, "Imaging for the diagnosis of hepatocellular carcinoma : a systematic review and meta-analysis", Hepatology, 67, pp.401~421 (2018)
  137. 이상민, "Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018", Korean Journal of Radiology, 22(7), pp.1066~1076 (2021), 대한영상의학회[DOI]
  138. 이선영, "Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging", Clinical and Molecular Hepatology, 26(3), pp.340~351 (2020), 대한간학회[DOI]
  139. Sangiovanni A, "The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis", Gut, 59, pp.638~644 (2010)
  140. Khalili K, "Optimization of imaging diagnosis of 1-2 cm hepatocellular carcinoma : an analysis of diagnostic performance and resource utilization", J Hepatol, 54, pp.723~728 (2011)
  141. Terzi E, "Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1, 006 nodules", J Hepatol, 68, pp.485~492 (2018)
  142. Hanna RF, "Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma", Abdom Radiol(NY), 41, pp.71~90 (2016)
  143. Yoon SH, "Multiphasic MDCT enhancement pattern of hepatocellular carcinoma smaller than 3 cm in diameter : tumor size and cellular differentiation", AJR Am J Roentgenol, 193, pp.W482~W489 (2009)
  144. Bolondi L, "Characterization of small nodules in cirrhosis by assessment of vascularity : the problem of hypovascular hepatocellular carcinoma", Hepatology, 42, pp.27~34 (2005)
  145. Kierans AS, "The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm : a meta-analysis", Radiology, 278, pp.82~94 (2016)
  146. Choi SH, "Diagnostic criteria for hepatocellular carcinoma ≤3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging", J Hepatol, 64, pp.1099~1107 (2016)
  147. Joo I, "Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acidenhanced MRI : can hypointensity on the hepatobiliary phase be used as an alternative to washout?", Eur Radiol, 25, pp.2859~2868 (2015)
  148. Ahn SJ, "Focal eosinophilic infiltration of the liver : gadoxetic acid-enhanced magnetic resonance imaging and diffusion-weighted imaging", J Comput Assist Tomogr, 35, pp.81~85 (2011)
  149. Kim DH, "Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma", J Hepatol, 71, pp.534~542 (2019)
  150. Choi SH, "Subtraction images of gadoxetic acid-enhanced MRI : effect on the diagnostic performance for focal hepatic lesions in patients at risk for hepatocellular carcinoma", AJR Am J Roentgenol, 209, pp.584~591 (2017)
  151. Kim SS, "Extended application of subtraction arterial phase imaging in LI-RADS version 2018 : a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI", Eur Radiol, 31, pp.1620~1629 (2021)
  152. Basha MAA, "Does a combined CT and MRI protocol enhance the diagnostic efficacy of LI-RADS in the categorization of hepatic observations? A prospective comparative study", Eur Radiol, 28, pp.2592~2603 (2018)
  153. Min JH, "Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography", Clin Gastroenterol Hepatol, 18, pp.2091~2100 (2020)
  154. Reynolds AR, "Infiltrative hepatocellular carcinoma : what radiologists need to know", Radiographics, 35, pp.371~386 (2015)
  155. Joo I, "Diagnostic accuracy of liver imaging reporting and data system(LI-RADS)v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acidenhanced MRI", J Magn Reson Imaging, 44, pp.1330~1338 (2016)
  156. Zhou C, "Combined hepatocellular carcinoma-cholangiocarcinoma : MRI features correlated with tumor biomarkers and prognosis", Eur Radiol, 32, pp.78~88 (2022)
  157. Wilson SR, "CEUS LI-RADS: algorithm, implementation, and key differences from CT", MRI, 2018, pp.43, 127~142
  158. Yang Y, "Perfluorobutane contrast-enhanced ultrasonography for the diagnosis of HCC: a systematic review and meta-analysis", Abdom Radiol(NY), 46, pp.4619~4628 (2021)
  159. Kang HJ, "Contrastenhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk", Radiology, 297, pp.108~116 (2020)
  160. Hsiao CY, "A prospective assessment of the diagnostic value of contrast-enhanced ultrasound, dynamic computed tomography and magnetic resonance imaging for patients with small liver tumors", J Clin Med, 8, pp.1353~ (2019)
  161. Cerny M, "LI-RADS version 2018 ancillary features at MRI", Radiographics, 38, pp.1973~2001 (2018)
  162. van der Pol CB, "Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review", Gastroenterology, 156, pp.976~986 (2019)
  163. Tanabe M, "Imaging outcomes of liver imaging reporting and data system version 2014 category 2, 3, and 4observations detected at CT and MR imaging", Radiology, 281, pp.129~139 (2016)
  164. Kim YY, "MRI ancillary features for LI-RADS category 3 and 4 observations : improved categorization to indicate the risk of hepatic malignancy", AJR Am J Roentgenol, 215, pp.1354~1362 (2020)
  165. Vernuccio F, "Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression", Eur J Radiol, 128, pp.109018~ (2020)
  166. Cho HJ, "Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver", Am J Gastroenterol, 112, pp.460~470 (2017)
  167. Singal AG, "International liver cancer association(ILCA)white paper on biomarker development for hepatocellular carcinoma", Gastroenterology, 160, pp.2572~2584 (2021)
  168. Kudo M, "Surveillance and diagnostic algorithm for hepatocellular carcinoma proposed by the liver cancer study group of Japan : 2014 update", Oncology, 87(1), pp.7~21 (2014)
  169. Park MJ, "Small hepatocellular carcinomas : improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns", Radiology, 264, pp.761~770 (2012)
  170. Park MJ, "Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma(≤ 2. 0 cm)in patients with hepatitis-induced liver cirrhosis", Acta Radiol, 54, pp.127~136 (2013)
  171. Yu MH, "Small(≤1-cm)hepatocellular carcinoma : diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging", Radiology, 271, pp.748~760 (2014)
  172. Jang KM, "Imaging features of subcentimeter hypointense nodules on gadoxetic acidenhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease", Acta Radiol, 56, pp.526~535 (2015)
  173. Lee YJ, "Hepatocellular carcinoma : diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis", Radiology, 275, pp.97~109 (2015)
  174. Park CJ, "Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC", Eur Radiol, 28, pp.1476~1484 (2018)
  175. Roskams T, "Pathology of early hepatocellular carcinoma : conventional and molecular diagnosis", Semin Liver Dis, 30, pp.17~25 (2010)
  176. Forner A, "Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis : prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma", Hepatology, 47, pp.97~104 (2008)
  177. Stigliano R, "Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC", Cancer Treat Rev, 33, pp.437~447 (2007)
  178. Silva MA, "Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer : a systematic review and meta-analysis", Gut, 57, pp.1592~1596 (2008)
  179. Tremosini S, "Prospective validation of an immunohistochemical panel(glypican 3, heat shock protein 70 and glutamine synthetase)in liver biopsies for diagnosis of very early hepatocellular carcinoma", Gut, 61, pp.1481~1487 (2012)
  180. WHO Classification of Tumours Editorial Board, "WHO classification of tumors: digestive system tumours" (2019), International Agency for Research on Cancer
  181. Rhee H, "Clinico-radio-pathological and molecular features of hepatocellular carcinomas with keratin 19expression", Liver Cancer, 9, pp.663~681 (2020)
  182. 김혜령, "Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors", Journal of Liver Cancer, 20(1), pp.17~24 (2020), 대한간암학회[DOI]
  183. Calderaro J, "Molecular and histological correlations in liver cancer", J Hepatol, 71, pp.616~630 (2019)
  184. Sherman M, "Biopsy for liver cancer : how to balance research needs with evidence-based clinical practice", Hepatology, 61, pp.433~436 (2015)
  185. Chen VL, "Role of biomarkers and biopsy in hepatocellular carcinoma", Clin Liver Dis, 24, pp.577~590 (2020)
  186. Tateishi R, "Diagnostic accuracy of tumor markers for hepatocellular carcinoma : a systematic review", Hepatol Int, 2, pp.17~30 (2008)
  187. Wong RJ, "Elevated alpha-fetoprotein : differential diagnosis-hepatocellular carcinoma and other disorders", Clin Liver Dis, 19, pp.309~323 (2015)
  188. Lok AS, "Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
  189. Hwang SH, "A new reporting system for diagnosis of hepatocellular carcinoma in chronic hepatitis B with clinical and gadoxetic acidenhanced MRI features", J Magn Reson Imaging, 55, pp.1877~1886 (2022)
  190. Joo I, "Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI : a multicenter study", Radiology, 296, pp.335~345 (2020)
  191. Mehta N, "Validation of a risk estimation of tumor recurrence after transplant(RETREAT)score for hepatocellular carcinoma recurrence after liver transplant", JAMA Oncol, 3, pp.493~500 (2017)
  192. Tabrizian P, "Recurrence of hepatocellular cancer after resection : patterns, treatments, and prognosis", Ann Surg, 261, pp.947~955 (2015)
  193. Gilbert ES, "Invited commentary : studies of workers exposed to low doses of radiation", Am J Epidemiol, 153, pp.319~322 (2001)
  194. Arthur C. Upton, "THE STATE OF THE ART IN THE 1990’S: NCRP REPORT No. 136 ON THE SCIENTIFIC BASES FOR LINEARITY IN THE DOSE-RESPONSE RELATIONSHIP FOR IONIZING RADIATION", Health Physics, 85(1), pp.15~22 (2003), Ovid Technologies (Wolters Kluwer Health)[DOI]
  195. Huda W, "Converting dose-length product to effective dose at CT", Radiology, 248, pp.995~1003 (2008)
  196. National Research Council, "Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2" (2006), National Academy of Sciences
  197. The 2007 recommendations of the international commission on radiological protection, "ICRP publication 103", Ann ICRP, 37, pp.1~332 (2007)
  198. Brenner DJ, "Impact of reduced patient life expectancy on potential cancer risks from radiologic imaging", Radiology, 261, pp.193~198 (2011)
  199. Takahashi H, "Can low-dose CT with iterative reconstruction reduce both the radiation dose and the amount of iodine contrast medium in a dynamic CT study of the liver?", Eur J Radiol, 83, pp.684~691 (2014)
  200. Pregler B, "Low tube voltage liver MDCT with sinogramaffirmed iterative reconstructions for the detection of hepatocellular carcinoma", Sci Rep, 7, pp.9460~ (2017)
  201. Nakamura Y, "Diagnostic value of deep learning reconstruction for radiation dose reduction at abdominal ultra-high-resolution CT", Eur Radiol, 31, pp.4700~4709 (2021)
  202. Yoon JH, "Double lowdose dual-energy liver CT in patients at high-risk of HCC : a prospective, randomized, single-center study", Invest Radiol, 55, pp.340~348 (2020)
  203. Park S, "Image quality in liver CT : low-dose deep learning vs standard-dose model-based iterative reconstructions", Eur Radiol, 32, pp.2865~2874 (2022)
  204. D’Amico G, "Natural history and prognostic indicators of survival in cirrhosis : a systematic review of 118 studies", J Hepatol, 44, pp.217~231 (2006)
  205. Llovet JM, "Systematic review of randomized trials for unresectable hepatocellular carcinoma : chemoembolization improves survival", Hepatology, 37, pp.429~442 (2003)
  206. 신동현, "밀란병기 이내로 진단된 간세포암 환자의 사망 원인분석", Journal of Liver Cancer, 16(2), pp.101~107 (2016), 대한간암학회
  207. Meier V, "Clinical staging of hepatocellular carcinoma", Dig Dis, 27, pp.131~141 (2009)
  208. 박수진, "Evaluation of the American Joint Committee on Cancer (AJCC) 8th Edition Staging System for Hepatocellular Carcinoma in 1,008 Patients with Curative Resection", Cancer Research and Treatment, 52(4), pp.1145~1152 (2020), 대한암학회[DOI]
  209. Shindoh J, "Microvascular invasion and a size cutoffvalue of 2 cm predict long-term oncological outcome in multiple hepatocellular carcinoma : reappraisal of the American joint committee on cancer staging system and validation using the surveillance, epidemiology, and end-results database", Liver Cancer, 9, pp.156~166 (2020)
  210. Ueno S, "Prognostic performance of the new classification of primary liver cancer of Japan(4th edition)for patients with hepatocellular carcinoma : a validation analysis", Hepatol Res, 24, pp.395~403 (2002)
  211. Nihon Kangan K, "General rules for the clinical and pathological study of primary liver cancer" (2010), Kanehara & Co
  212. 김인규, "The 7th", 8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma, 2019, pp.60(2), 140~147[DOI]
  213. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : the 2022 update", J Hepatol, 76, pp.681~693 (2022)
  214. Jordi Bruix, "Management of hepatocellular carcinoma: An update", Hepatology, 53(3), pp.1020~1022 (2011), Ovid Technologies (Wolters Kluwer Health)[DOI]
  215. Yau T, "Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma", Gastroenterology, 146, pp.1691~1700 (2014)
  216. Sohn JH, "Validation of the Hong Kong liver cancer staging system in determining prognosis of the north American patients following intra-arterial therapy", Clin Gastroenterol Hepatol, 15, pp.746~755 (2017)
  217. Uchino K, "Hepatocellular carcinoma with extrahepatic metastasis : clinical features and prognostic factors", Cancer, 117, pp.4475~4483 (2011)
  218. Benson AB, "Hepatobiliary cancers, version 2. 2021, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 19, pp.541~565 (2021)
  219. Park JW, "A prospective evaluation of 18F-FDG and 11C-acetate PET", CT for detection of primary and metastatic hepatocellular carcinoma, 2008, pp.49, 1912~1921
  220. Lee JE, "Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography", computed tomography scan, 2012, pp.18, 2979~2987
  221. Sugiyama M, "18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma", J Gastroenterol, 39, pp.961~968 (2004)
  222. Cho Y, "Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma", PLoS One, 9, pp.e105679~ (2014)
  223. fluorodeoxyglucose positron emission tomography with computed tomography to crosssectional imaging improves staging and alters management in hepatocellular carcinoma, "Liver Transpl", 2020, 774~784
  224. Chalaye J, "Positron emission tomography", computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma, 2018, pp.69, 336~344
  225. Rilling WS, "Multidisciplinary management of hepatocellular carcinoma", J Vasc Interv Radiol, 13, pp.S259~S263 (2002)
  226. Colombo M, "Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma : a European perspective", Eur J Gastroenterol Hepatol, 25, pp.639~651 (2013)
  227. Sinn DH, "Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients", PLoS One, 14, pp.e0210730~ (2019)
  228. Yopp AC, "Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome", Ann Surg Oncol, 21, pp.1287~1295 (2014)
  229. Serper M, "Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality", Gastroenterology, 152, pp.1954~1964 (2017)
  230. Charriere B, "Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings", J Surg Oncol, 115, pp.330~336 (2017)
  231. Chang TT, "Implementation of a multidisciplinary treatment team for hepatocellular cancer at a veterans affairs medical center improves survival", HPB(Oxford), 10, pp.405~411 (2008)
  232. Cohen GS, "Multidisciplinary management of hepatocellular carcinoma : a model for therapy", J Multidiscip Healthc, 6, pp.189~195 (2013)
  233. Burak KW, "An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma(HCC) : the Alberta HCC algorithm", Can J Gastroenterol, 24, pp.643~650 (2010)
  234. Chan AC, "Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening", Ann Surg, 247, pp.666~673 (2008)
  235. Taylor C, "Multidisciplinary team working in cancer : what is the evidence", BMJ, 340, pp.c951~ (2010)
  236. Fennell ML, "The organization of multidisciplinary care teams : modeling internal and external influences on cancer care quality", J Natl Cancer Inst Monogr, 2010, pp.72~80 (2010)
  237. Gish RG, "Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma", Expert Rev Gastroenterol Hepatol, 6, pp.173~185 (2012)
  238. Litton G, "Multidisciplinary cancer care with a patient and physician satisfaction focus", J Oncol Pract, 6, pp.e35~e37 (2010)
  239. Lang H, "Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis", Br J Surg, 92, pp.198~202 (2005)
  240. Capussotti L, "Major liver resections for hepatocellular carcinoma on cirrhosis : early and long-term outcomes", Liver Transpl (2004)
  241. Poon RT, "Improving survival results after resection of hepatocellular carcinoma : a prospective study of 377 patients over 10 years", Ann Surg, 234, pp.63~70 (2001)
  242. Andreou A, "Improved long-term survival after major resection for hepatocellular carcinoma : a multicenter analysis based on a new definition of major hepatectomy", J Gastrointest Surg, 17, pp.66~77 (2013)[DOI]
  243. Huang J, "A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy", J Cancer Res Clin Oncol, 139, pp.1709~1719 (2013)
  244. Lee EC, "Survival analysis after liver resection for hepatocellular carcinoma : a consecutive cohort of 1002 patients", J Gastroenterol Hepatol, 32, pp.1055~1063 (2017)
  245. Torzilli G, "A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers : is it adherent to the EASL", AASLD recommendations? : An observational study of the HCC east-west study group, 2013, pp.257, 929~937
  246. Kim JH, "Saftey and long-term outcome following major hepatectomy for epatocellular carcinoma combined with compensated liver cirrhosis", J Korean Surg Soc, 70, pp.445~450 (2006)
  247. Minagawa M, "Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma", Ann Surg, 238, pp.703~710 (2003)
  248. Finkelstein SD, "Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma", Hepatology, 37, pp.871~879 (2003)
  249. Imamura H, "Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy", J Hepatol, 38, pp.200~207 (2003)
  250. Kaibori M, "Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma", J Surg Oncol, 102, pp.462~468 (2010)
  251. Li SH, "Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection", Asian Pac J Cancer Prev, 14, pp.4759~4763 (2013)
  252. Nathan H, "Predictors of survival after resection of early hepatocellular carcinoma", Ann Surg, 249, pp.799~805 (2009)
  253. Portolani N, "Early and late recurrence after liver resection for hepatocellular carcinoma : prognostic and therapeutic implications", Ann Surg, 243, pp.229~235 (2006)
  254. Wu JC, "Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma", J Hepatol, 51, pp.890~897 (2009)
  255. Zhou L, "Prognostic factors of solitary large hepatocellular carcinoma : the importance of differentiation grade", Eur J Surg Oncol, 37, pp.521~525 (2011)
  256. Kim YI, "Higher ratio of serum alpha-fetoprotein could predict outcomes in patients with hepatitis B virus-associated hepatocellular carcinoma and normal alanine aminotransferase", PLoS One, 11, pp.e0157299~ (2016)
  257. Kim DY, "PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection", Oncology, 72(1), pp.52~57 (2007)
  258. Pugh RN, "Transection of the oesophagus for bleeding oesophageal varices", Br J Surg, 60, pp.646~649 (1973)
  259. Belghiti J, "Seven hundred forty-seven hepatectomies in the 1990s : an update to evaluate the actual risk of liver resection", J Am Coll Surg, 191, pp.38~46 (2000)
  260. Farges O, "Risk of major liver resection in patients with underlying chronic liver disease : a reappraisal", Ann Surg, 229, pp.210~215 (1999)
  261. Masatoshi Makuuchi, "The surgical approach to HCC: Our progress and results in Japan", Liver Transplantation, 10(S2), pp.S46~S52 (2004), Ovid Technologies (Wolters Kluwer Health)[DOI]
  262. Fan ST, "Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis", Arch Surg, 130, pp.198~203 (1995)
  263. Llovet JM, "Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma : resection versus transplantation", Hepatology, 30, pp.1434~1440 (1999)
  264. 안민, "간접적으로 확인한 간문맥압항진증이 간세포암종 환자의 간절제술 후 합병증 발생과 예후에 미치는 영향", Clinical and Molecular Hepatology, 12(4), pp.553~561 (2006), 대한간학회
  265. Choi GH, "Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma", Liver Int, 31, pp.485~493 (2011)
  266. Capussotti L, "Portal hypertension : contraindication to liver surgery?", World J Surg, 30, pp.992~999 (2006)
  267. Cucchetti A, "Is portal hypertension a contraindication to hepatic resection?", Ann Surg, 250, pp.922~928 (2009)
  268. He W, "The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients : a propensity score matching analysis", BMC Cancer, 15, pp.263~ (2015)
  269. Ishizawa T, "Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma", Gastroenterology, 134, pp.1908~1916 (2008)
  270. Guglielmi A, "How much remnant is enough in liver resection?", Dig Surg, 29, pp.6~17 (2012)
  271. Cescon M, "Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma", Ann Surg, 256, pp.706~712 (2012)[DOI]
  272. Hu H, "Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma : the evidence from ultrasound data", Eur Radiol, 28, pp.877~885 (2018)
  273. Kim SU, "Prediction of postoperative hepatic insufficiency by liver stiffness measurement(FibroScan®)before curative resection of hepatocellular carcinoma : a pilot study", Hepatol Int, 2, pp.471~477 (2008)
  274. Wong JS, "Liver stiffness measurement by transient elastography as a predictor on posthepatectomy outcomes", Ann Surg, 257, pp.922~928 (2013)
  275. Li C, "FibroScan predicts ascites after liver resection for hepatitis B virus-related hepatocellular carcinoma : a prospective cohort study", Int J Surg, 20, pp.21~25 (2015)
  276. Chong CC, "Liver stiffness measurement predicts high-grade post-hepatectomy liver failure : a prospective cohort study", J Gastroenterol Hepatol, 32, pp.506~514 (2017)
  277. Rajakannu M, "Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma", Surgery, 162, pp.766~774 (2017)
  278. Huang Z, "Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection : a meta-analysis", PLoS One, 13, pp.e0190512~ (2018)
  279. Hammerstingl R, "Diagnostic efficacy of gadoxetic acid(primovist)-enhanced MRI and spiral CT for a therapeutic strategy : comparison with intraoperative and histopathologic findings in focal liver lesions", Eur Radiol, 18, pp.457~467 (2008)
  280. Kim SH, "Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma", AJR Am J Roentgenol, 192, pp.1675~1681 (2009)
  281. Ippolito D, "Estimating liver function in a large cirrhotic cohort : signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI", Dig Liver Dis, 51, pp.1438~1445 (2019)
  282. Lin CY, "Dynamic-contrastenhanced magnetic resonance imaging of cirrhotic liver parenchyma : a comparison between gadolinium-diethylenetriamine pentaacetic acid and gadolinium-ethoxybenzyldiethylenetriamine pentaacetic acid", J Chin Med Assoc, 78, pp.666~672 (2015)
  283. Kubota K, "Correlation of liver parenchymal gadoliniumethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma", Oncol Lett, 3, pp.990~994 (2012)
  284. Haimerl M, "Gd-EOB-DTPA-enhanced MRI for evaluation of liver function : comparison between signal-intensity-based indices and T1 relaxometry", Sci Rep, 7, pp.43347~ (2017)
  285. Lin CY, "18F-FDG PET or PET", CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma : a systematic review and meta-analysis, 2012, pp.81, 2417~2422
  286. Koneru B, "A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma", Ann Surg, 241, pp.622~628 (2005)
  287. Liu L, "Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma : a metaanalysis", PLoS One, 8, pp.e64261~ (2013)
  288. Peng T, "No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma : a propensity score matching analysis", Clin Transl Oncol, 20, pp.719~728 (2018)
  289. Wada H, "Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery : a multicenter analysis", Surg Today, 48, pp.73~79 (2018)
  290. Tsujita E, "Selective hepatic vascular exclusion for the hepatic resection of HCC", Hepatogastroenterology, 54, pp.527~530 (2007)
  291. Jongerius IM, "Goal-directed fluid therapy vs. low central venous pressure during major open liver resections (GALILEO):a surgeon- and patient-blinded randomized controlled trial", HPB(Oxford), 23, pp.1578~1585 (2021)
  292. Lin N, "Does the intermittent pringle maneuver affect the recurrence following surgical resection for hepatocellular carcinoma? A systematic review", PLoS One, 15, pp.e0229870~ (2020)
  293. Khajeh E, "Meta-analysis of the effect of the pringle maneuver on long-term oncological outcomes following liver resection", Sci Rep, 11, pp.3279~ (2021)
  294. Cucchetti A, "Anatomic versus nonanatomic resection in cirrhotic patients with early hepatocellular carcinoma", Surgery, 155, pp.512~521 (2014)
  295. Ishii M, "Propensity score analysis demonstrated the prognostic advantage of anatomical liver resection in hepatocellular carcinoma", World J Gastroenterol, 20, pp.3335~3342 (2014)
  296. Kaibori M, "Comparison of anatomic and non-anatomic hepatic resection for hepatocellular carcinoma", J Hepatobiliary Pancreat Sci, 24, pp.616~626 (2017)
  297. Kudo A, "Anatomic resection reduces the recurrence of solitary hepatocellular carcinoma ≤5 cm without macrovascular invasion", Am J Surg, 207, pp.863~869 (2014)
  298. Sakoda M, "Survival benefits of small anatomical resection of the liver for patients with hepatocellular carcinoma and impaired liver function, based on new-era imaging studies", J Cancer, 7, pp.1029~1036 (2016)
  299. Zhao H, "Anatomical versus non-anatomical resection for solitary hepatocellular carcinoma without macroscopic vascular invasion : a propensity score matching analysis", J Gastroenterol Hepatol, 32, pp.870~878 (2017)
  300. Huang X, "non-anatomical resection on the longterm outcomes for patients undergoing hepatic resection for hepatocellular carcinoma", HPB(Oxford), 19, pp.843~849 (2017)
  301. Feng X, "A double blinded prospective randomized trial comparing the effect of anatomic versus non-anatomic resection on hepatocellular carcinoma recurrence", HPB(Oxford), 19, pp.667~674 (2017)
  302. Moris D, "Anatomic versus non-anatomic resection for hepatocellular carcinoma : a systematic review and meta-analysis", Eur J Surg Oncol, 44, pp.927~938 (2018)
  303. Sun Z, "Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion : a systematic review and meta-analysis", Asian J Surg, 44, pp.1143~1150 (2021)
  304. Famularo S, "Is it just a matter of surgical extension to achieve the cure of hepatocarcinoma? A meta-analysis of propensitymatched and randomized studies for anatomic versus parenchyma-sparing liver resection", J Gastrointest Surg, 25, pp.94~103 (2021)
  305. Shi M, "Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma : a prospective randomized trial", Ann Surg, 245, pp.36~43 (2007)
  306. Zhong FP, "Prognostic impact of surgical margin in patients with hepatocellular carcinoma: a meta-analysis", Medicine(Baltimore), 96, pp.e8043~ (2017)
  307. Lazzara C, "Does the margin width influence recurrence rate in liver surgery for hepatocellular carcinoma smaller than 5cm?", Eur Rev Med Pharmacol Sci, 21, pp.523~529 (2017)
  308. Eguchi S, "Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey", Surgery, 143, pp.469~475 (2008)
  309. Suh KS, "Systematic hepatectomy for small hepatocellular carcinoma in Korea", J Hepatobiliary Pancreat Surg, 12, pp.365~370 (2005)
  310. Wakai T, "Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma", Ann Surg Oncol, 14, pp.1356~1365 (2007)
  311. 김인숙, "절제 가능한 간세포암에서 수술 전 경동맥화학색전술의 효과", 대한내과학회지, 69(6), pp.614~621 (2005), 대한내과학회
  312. Wu CC, "Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma : a reappraisal", Br J Surg, 82, pp.122~126 (1995)
  313. Jianyong L, "Preoperative adjuvant transarterial chemoembolization cannot improve the long term outcome of radical therapies for hepatocellular carcinoma", Sci Rep, 7, pp.41624~ (2017)
  314. Hayashi H, "Functional assessment versus conventional volumetric assessment in the prediction of operative outcomes after major hepatectomy", Surgery, 157, pp.20~26 (2015)
  315. Nishio T, "Prediction of posthepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma", Surgery, 159, pp.399~408 (2016)
  316. Beppu T, "Portal vein embolization followed by right-side hemihepatectomy for hepatocellular carcinoma patients : a Japanese multi-institutional study", J Am Coll Surg, 222, pp.1138~1148 (2016)
  317. Pandanaboyana S, "A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection", Surgery, 157, pp.690~698 (2015)
  318. Schadde E, "Prediction of mortality after ALPPS stage-1 : an analysis of 320 patients from the international ALPPS registry", Ann Surg, 262, pp.780~785 (2015)[DOI]
  319. Chan A, "ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma : a changing paradigm in modulation of future liver remnant before major hepatectomy", Ann Surg, 273, pp.957~965 (2021)
  320. Belghiti J, "Liver hanging maneuver : a safe approach to right hepatectomy without liver mobilization", J Am Coll Surg, 193, pp.109~111 (2001)
  321. Tang JX, "Anterior vs conventional approach right hepatic resection for large hepatocellular carcinoma : a systematic review and meta-analysis", World J Gastroenterol, 23, pp.7917~7929 (2017)
  322. Han HS, "Laparoscopic versus open liver resection for hepatocellular carcinoma : case-matched study with propensity score matching", J Hepatol, 63, pp.643~650 (2015)
  323. Kabir T, "Laparoscopic versus open resection of hepatocellular carcinoma in patients with cirrhosis : meta-analysis", Br J Surg, 109, pp.21~29 (2021)
  324. Cheung TT, "Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis : a single-center experience", Ann Surg, 257, pp.506~511 (2013)
  325. Wang X, "Consensus guidelines for the use of fluorescence imaging in hepatobiliary surgery", Ann Surg, 274, pp.97~106 (2021)
  326. Andrea Benedetti Cacciaguerra, "Outcome of major hepatectomy in cirrhotic patients; does surgical approach matter? A propensity score matched analysis", Journal of Hepato-Biliary-Pancreatic Sciences, 29(11), pp.1226~1239 (2021), Wiley[DOI]
  327. Yoon YI, "Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis : a propensity score matched analysis", Ann Surg, 265, pp.856~863 (2017)
  328. Berardi G, "Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis", J Hepatol, 72, pp.75~84 (2020)
  329. Troisi RI, "Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis : multicentre propensity score-matched study", Br J Surg, 108, pp.196~204 (2021)
  330. Ruzzenente A, "Minimally invasive versus open liver resection for hepatocellular carcinoma in the setting of portal vein hypertension : results of an international multi-institutional analysis", Ann Surg Oncol, 27, pp.3360~3371 (2020)
  331. Pesi B, "Robotic versus open liver resection in hepatocarcinoma : surgical and oncological outcomes", Surg Laparosc Endosc Percutan Tech, 31, pp.468~474 (2021)
  332. Zhou YM, "Safety and efficacy of partial hepatectomy for huge(≥10 cm)hepatocellular carcinoma : a systematic review", Med Sci Monit, 17, pp.76~83 (2011)
  333. Hwang S, "Long-term outcome after resection of huge hepatocellular carcinoma ≥ 10 cm : single-institution experience with 471patients", World J Surg, 39, pp.2519~2528 (2015)
  334. Wei CY, "Comparison of prognosis between surgical resection and transarterial chemoembolization for patients with solitary huge hepatocellular carcinoma", Ann Transl Med, 8, pp.238~ (2020)
  335. Yue YY, "Hepatic resection is associated with improved long-term survival compared to radio-frequency ablation in patients with multifocal hepatocellular carcinoma", Front Oncol, 10, pp.110~ (2020)
  336. Lu L, "Hepatic resection versus transarterial chemoembolization for intermediate-stage hepatocellular carcinoma : a cohort study", Front Oncol, 11, pp.618937~ (2021)
  337. Fukami Y, "Liver resection for multiple hepatocellular carcinomas : a Japanese nationwide survey", Ann Surg, 272, pp.145~154 (2020)
  338. Iakova P, "Aging reduces proliferative capacities of liver by switching pathways of C", EBPalpha growth arrest, 2003, pp.113, 495~506
  339. Mullen JT, "Hepatic insufficiency and mortality in 1, 059 noncirrhotic patients undergoing major hepatectomy", J Am Coll Surg, 204, pp.854~862 (2007)[DOI]
  340. Nishikawa H, "Treatment for hepatocellular carcinoma in elderly patients : a literature review", J Cancer, 4, pp.635~643 (2013)
  341. Aoki T, "Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma : an analysis of 1160cases from a nationwide survey", Ann Surg, 259, pp.532~542 (2014)
  342. Li J, "Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma : a case-control study", World J Gastroenterol, 20, pp.9121~9127 (2014)
  343. Kwon JH, "Surgical outcomes of spontaneously ruptured hepatocellular carcinoma", J Gastrointest Surg, 25, pp.941~953 (2021)
  344. Hyung Soon Lee, "Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea", Annals of Surgical Treatment and Research, 96(6), pp.275~282 (2019), 대한외과학회[DOI]
  345. Chan WH, "Impact of spontaneous tumor rupture on prognosis of patients with T4 hepatocellular carcinoma", J Surg Oncol, 113, pp.789~795 (2016)
  346. Wu JJ, "Spontaneous rupture of hepatocellular carcinoma : optimal timing of partial hepatectomy", Eur J Surg Oncol, 45, pp.1887~1894 (2019)
  347. Schwarz L, "Bleeding recurrence and mortality following interventional management of spontaneous HCC rupture : results of a multicenter European study", World J Surg, 42, pp.225~232 (2018)
  348. Zhou C, "Emergency transarterial embolization followed by staged hepatectomy versus emergency hepatectomy for ruptured hepatocellular carcinoma : a single-center, propensity score matched analysis", Jpn J Radiol, 38, pp.1090~1098 (2020)
  349. Kokudo T, "Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion", J Hepatol, 65, pp.938~943 (2016)
  350. 이정민, "Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis", Clinical and Molecular Hepatology, 22(1), pp.160~167 (2016), 대한간학회
  351. Kokudo T, "Liver resection for hepatocellular carcinoma associated with hepatic vein invasion : a Japanese nationwide survey", Hepatology, 66, pp.510~517 (2017)
  352. Zun-Yi Zhang, "Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis", Medicine, 98(50), pp.e18362~ (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
  353. Mei J, "Resection vs. sorafenib for hepatocellular carcinoma with macroscopic vascular invasion : a real world, propensity score matched analytic study", Front Oncol, 10, pp.573~ (2020)
  354. Govalan R, "Comparison of surgical resection and systemic treatment for hepatocellular carcinoma with vascular invasion : national cancer database analysis", Liver Cancer, 10, pp.407~418 (2021)
  355. Moon DB, "Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus : a Korean multicenter study", World J Surg, 37, pp.443~451 (2013)
  356. Kim DS, "Surgical outcomes of hepatocellular carcinoma with bile duct tumor thrombus : a Korea-Japan multicenter study", Ann Surg, 271, pp.913~921 (2020)
  357. 김종만, "Realization of improved outcomes following liver resection in hepatocellular carcinoma patients aged 75 years and older", Annals of Surgical Treatment and Research, 101(5), pp.257~265 (2021), 대한외과학회
  358. Kim JM, "Predicting hepatocellular carcinoma recurrence beyond milan criteria after liver resection for solitary hepatocellular carcinoma", J Gastrointest Surg, 24, pp.2219~2227 (2020)
  359. Yoon YI, "Salvage living donor liver transplantation versus repeat liver resection for patients with recurrent hepatocellular carcinoma and Child-Pugh class A liver cirrhosis : a propensity scorematched comparison", Am J Transplant, 22, pp.165~176 (2022)
  360. Xia Y, "Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma : a randomized clinical trial", JAMA Oncology, 6, pp.255~263 (2020)
  361. Wang HL, "salvage liver transplantation or curative locoregional therapy", Medicine(Baltimore), 98, pp.e14498~ (2019)
  362. Okada S, "Predictive factors for postoperative recurrence of hepatocellular carcinoma", Gastroenterology, 106, pp.1618~1624 (1994)
  363. Shirabe K, "Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy : univariate and multivariate analyses", Hepatology, 14, pp.802~805 (1991)
  364. Poon RT, "Intrahepatic recurrence after curative resection of hepatocellular carcinoma : long-term results of treatment and prognostic factors", Ann Surg, 229, pp.216~222 (1999)
  365. Adachi E, "Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma", Gastroenterology, 108, pp.768~775 (1995)
  366. Lee S, "Effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation", Ann Surg, 273, pp.564~571 (2021)
  367. Jung SM, "Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma", J Gastrointest Surg, 23, pp.304~311 (2019)
  368. Agopian VG, "Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within milan criteria undergoing liver transplantation : analysis of 3601 patients from the US multicenter HCC transplant consortium", Ann Surg, 266, pp.525~535 (2017)
  369. Kim BK, "Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection", Liver Int, 28, pp.393~401 (2008)
  370. Ohkubo K, "Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma", Cancer, 94, pp.2663~2668 (2002)
  371. Hung IF, "Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection", Am J Gastroenterol, 103, pp.1663~1673 (2008)
  372. Kubo S, "Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C", Jpn J Cancer Res, 90, pp.1076~1080 (1999)
  373. Chan DL, "Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma-a systematic review", Surg Oncol, 22, pp.e23~e30 (2013)
  374. Kim JM, "Living donor liver transplantation should be cautiously considered as initial treatment in recurrent hepatocellular carcinoma within the Milan criteria after curative liver resection", Ann Transl Med, 8, pp.288~ (2020)
  375. Chan DL, "Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma", J Gastroenterol Hepatol, 29, pp.31~41 (2014)
  376. Poon RT, "Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy", J Am Coll Surg, 195, pp.311~318 (2002)
  377. Erridge S, "Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma", Br J Surg, 104, pp.1433~1442 (2017)
  378. Peng ZW, "Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone : a prospective randomized trial", Radiology, 262, pp.689~700 (2012)
  379. Shim JH, "Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection", Ann Surg Oncol, 17, pp.869~877 (2010)
  380. Shimada K, "Analysis of prognostic factors affecting survival after initial recurrence and treatment efficacy for recurrence in patients undergoing potentially curative hepatectomy for hepatocellular carcinoma", Ann Surg Oncol, 14, pp.2337~2347 (2007)
  381. Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
  382. Mazzaferro V, "Milan criteria in liver transplantation for hepatocellular carcinoma : an evidence-based analysis of 15 years of experience", Liver Transpl (2011)
  383. Clavien PA, "Recommendations for liver transplantation for hepatocellular carcinoma : an international consensus conference report", Lancet Oncol, 13, pp.e11~e22 (2012)
  384. Germani G, "Which matters most: number of tumors, size of the largest tumor, or total tumor volume?", Liver Transpl, 17(2), pp.58~66 (2011)
  385. Sugimachi K, "Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma", Transplantation, 91, pp.570~574 (2011)
  386. Lee JM, "Imaging diagnosis and staging of hepatocellular carcinoma", Liver Transpl (2011)
  387. Lv J, "Investigating the value of pretreatment 18F-FDG PET", CT in predicting the pathological characteristic of hepatocellular carcinoma and recurrence after liver transplantation, 2021, pp.46, 2490~2497
  388. Kang YK, "Composite criteria using clinical and FDG PET", CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation, 2019, pp.29, 6009~6017
  389. Lim C, "18F-FDG PET", CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: a prospective observational study, 2019, pp.21, 739~747
  390. Alcorn JB, "Changes to OPTN by laws and policies from actions at November board of directors meeting" (2016)
  391. Heimbach JK, "Evolution of liver transplant selection criteria and U. S. allocation policy for patients with hepatocellular carcinoma", Semin Liver Dis, 40, pp.358~364 (2020)
  392. Korean Organ Donation Agency, "Korea Network for Organ Sharing (KONOS) Registry", ~ (2020)
  393. Freeman RB, "Waiting list removal rates among patients with chronic and malignant liver diseases", Am J Transplant, 6, pp.1416~1421 (2006)
  394. Yao FY, "Liver transplantation for hepatocellular carcinoma : expansion of the tumor size limits does not adversely impact survival", Hepatology, 33, pp.1394~1403 (2001)
  395. Llovet JM, "Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation", Gut, 50, pp.123~128 (2002)
  396. Mazzaferro V, "Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation : a prospective study", Ann Surg, 240, pp.900~909 (2004)
  397. Pomfret EA, "Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States", Liver Transpl, 16, pp.262~278 (2010)
  398. Mehta N, "Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation : proposing a wait time"sweet spot"", Transplantation, 101, pp.2071~2078 (2017)
  399. Kollmann D, "Bridging to liver transplantation in HCC patients", Langenbecks Arch Surg, 402, pp.863~871 (2017)
  400. Decaens T, "Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma", Liver Transpl, 11, pp.767~775 (2005)
  401. Lesurtel M, "Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma : an evidencebased analysis", Am J Transplant, 6, pp.2644~2650 (2006)
  402. Pelletier SJ, "An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data", Liver Transpl, 15, pp.859~868 (2009)
  403. Kulik L, "Therapies for patients with hepatocellular carcinoma awaiting liver transplantation : a systematic review and metaanalysis", Hepatology, 67, pp.381~400 (2018)
  404. Si T, "Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma : a meta-analysis", J Gastroenterol Hepatol, 32, pp.1286~1294 (2017)
  405. Porrett PM, "Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era", Liver Transpl, 12, pp.665~673 (2006)
  406. Chapman WC, "Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation", Ann Surg, 248, pp.617~625 (2008)
  407. Lee MW, "Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation : a 10-year intention-to-treat analysis", Hepatology, 65, pp.1979~1990 (2017)
  408. Yao FY, "Liver transplantation for hepatocellular carcinoma : analysis of survival according to the intention-to-treat principle and dropout from the waiting list", Liver Transpl, 8, pp.873~883 (2002)
  409. Yao FY, "Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation : an intentionto-treat analysis", Hepatology, 48, pp.819~827 (2008)
  410. Sapisochin G, "Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-to-treat analysis", J Hepatol, 67, pp.92~99 (2017)
  411. De Luna W, "Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation", Am J Transplant, 9, pp.1158~1168 (2009)
  412. Roayaie S, "Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters", Ann Surg, 235, pp.533~539 (2002)
  413. Yao FY, "A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation", Liver Transpl, 11, pp.1505~1514 (2005)
  414. Lewandowski RJ, "A comparative analysis of transarterial downstaging for hepatocellular carcinoma : chemoembolization versus radioembolization", Am J Transplant, 9, pp.1920~1928 (2009)
  415. Parikh ND, "Downstaging hepatocellular carcinoma : a systematic review and pooled analysis", Liver Transpl, 21, pp.1142~1152 (2015)
  416. Mehta N, "Downstaging outcomes for hepatocellular carcinoma : results from the multicenter evaluation of reduction in tumor size before liver transplantation(MERITS-LT)consortium", Gastroenterology, 161, pp.1502~1512 (2021)
  417. Mazzaferro V, "Liver transplantation in hepatocellular carcinoma after tumour downstaging(XXL) : a randomised, controlled, phase 2b", 3 trial, 2020, pp.21, 947~956
  418. Chapman WC, "Liver transplantation for advanced hepatocellular carcinoma after downstaging without up-front stage restrictions", J Am Coll Surg, 224, pp.610~621 (2017)
  419. Kim JH, "Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy: a retrospective cohort study", Medicine(Baltimore), 95, pp.e4735~ (2016)
  420. Ravaioli M, "Liver transplantation for hepatocellular carcinoma : results of down-staging in patients initially outside the Milan selection criteria", Am J Transplant, 8, pp.2547~2557 (2008)
  421. Yao FY, "Downstaging of hepatocellular cancer before liver transplant : long-term outcome compared to tumors within Milan criteria", Hepatology, 61, pp.1968~1977 (2015)
  422. Halazun KJ, "Predictors of outcome after liver transplantation for hepatocellular carcinoma(HCC)beyond Milan criteria", Int J Surg (2020)
  423. DiNorcia J, "Pathologic response to pretransplant locoregional therapy is predictive of patient outcome after liver transplantation for hepatocellular carcinoma : analysis from the US multicenter HCC transplant consortium", Ann Surg, 271, pp.616~624 (2020)
  424. Ho MH, "Locoregional therapy-induced tumor necrosis as a predictor of recurrence after liver transplant in patients with hepatocellular carcinoma", Ann Surg Oncol, 18, pp.3632~3639 (2011)
  425. Kardashian A, "Liver transplantation outcomes in a U. S. multicenter cohort of 789 patients with hepatocellular carcinoma presenting beyond milan criteria", Hepatology, 72, pp.2014~2028 (2020)
  426. Mehta N, "Alpha-fetoprotein decrease from > 1, 000 to < 500 ng", mL in patients with hepatocellular carcinoma leads to improved posttransplant outcomes, 2019, pp.69, 1193~1205
  427. Bargellini I, "Trends in utilization of transarterial treatments for hepatocellular carcinoma : results of a survey by the italian society of interventional radiology", Cardiovasc Intervent Radiol, 37, pp.438~444 (2014)
  428. Korean Organ Donation Agency, "Korea Network for Organ Sharing (KONOS) Registry", ~ (2017)
  429. KONOS annual report, "KONOS", KONOS, ~ (2019)
  430. Grant RC, "Living vs. deceased donor liver transplantation for hepatocellular carcinoma : a systematic review and meta-analysis", Clin Transplant, 27, pp.140~147 (2013)
  431. Liang W, "Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma : a metaanalysis", Liver Transpl, 18, pp.1226~1236 (2012)
  432. Tan DJH, "A meta-analysis on the rate of hepatocellular carcinoma recurrence after liver transplant and associations to etiology, alpha-fetoprotein, income and ethnicity", J Clin Med, 10, pp.238~ (2021)
  433. Azoulay D, "Living or brain-dead donor liver transplantation for hepatocellular carcinoma : a multicenter, western, intent-to-treat cohort study", Ann Surg, 266, pp.1035~1044 (2017)
  434. Bhangui P, "Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma : living versus deceased donor transplantation", Hepatology, 53, pp.1570~1579 (2011)
  435. Kulik LM, "Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma : results of the A2ALL cohort", Am J Transplant, 12, pp.2997~3007 (2012)
  436. Kulik L, "Living donor liver transplantation for hepatocellular carcinoma", Gastroenterology, 5(1), pp.277~282 (2004)
  437. Sarasin FP, "Living donor liver transplantation for early hepatocellular carcinoma : a life-expectancy and cost-effectiveness perspective", Hepatology, 33, pp.1073~1079 (2001)
  438. Kwon CH, "HCC in living donor liver transplantation : can we expand the Milan criteria?", Dig Dis, 25, pp.313~319 (2007)
  439. Suh KS, "Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria", Dig Dis, 25, pp.329~333 (2007)
  440. Choi HJ, "Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation", World J Gastroenterol, 19, pp.4737~4744 (2013)
  441. Lee SG, "Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center", Liver Transpl, 14, pp.935~945 (2008)
  442. Sugawara Y, "Living donor liver transplantation for hepatocellular carcinoma : Tokyo University series", Dig Dis, 25, pp.310~312 (2007)
  443. Ito T, "Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation", Liver Transpl, 13, pp.1637~1644 (2007)
  444. Taketomi A, "Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation", Transplantation, 87, pp.531~537 (2009)
  445. Todo S, "Extending indication : role of living donor liver transplantation for hepatocellular carcinoma", Liver Transpl (2007)
  446. Lee JH, "Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the milan criteria", Ann Surg, 263, pp.842~850 (2016)
  447. Lee SD, "Proposal of new expanded selection criteria using total tumor size and(18)F-fluorodeoxyglucose-positron emission tomography", computed tomography for living donor liver transplantation in patients with hepatocellular carcinoma : the national cancer center Korea criteria, 2016, pp.6, 411~422
  448. Kornberg A, "Combining 18F-FDG positron emission tomography with up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma", Sci Rep, 7, pp.14176~ (2017)
  449. Takada Y, "Significance of preoperative fluorodeoxyglucosepositron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients : a Japanese multicenter study", J Hepatobiliary Pancreat Sci, 24, pp.49~57 (2017)
  450. Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria", Gastroenterology, 143, pp.986~994 (2012)
  451. Notarpaolo A, "Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC", J Hepatol, 66, pp.552~559 (2017)
  452. Alim A, "Living donor liver transplantation : the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria", Cancer Control, 28, pp.10732748211011960~ (2021)
  453. Kim YS, "Tenyear outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma : analysis of prognostic factors", J Hepatol, 58, pp.89~97 (2013)
  454. Shin M, "Donor morbidity including biliary complications in living-donor liver transplantation : single-center analysis of 827 cases", Transplantation, 93, pp.942~948 (2012)
  455. Kim KH, "Comparison of open and laparoscopic live donor left lateral sectionectomy", Br J Surg, 98, pp.1302~1308 (2011)
  456. Hwang S, "Lessons learned from 1, 000 living donor liver transplantations in a single center : how to make living donations safe", Liver Transpl, 12, pp.920~927 (2006)
  457. Yi NJ, "Threequarters of right liver donors experienced postoperative complications", Liver Transpl, 13, pp.797~806 (2007)
  458. Kim SJ, "Surgical outcome of right liver donors in living donor liver transplantation : single-center experience with 500 cases", J Gastrointest Surg, 16, pp.1160~1170 (2012)
  459. Lee JG, "Donor safety in living donor liver transplantation : the Korean organ transplantation registry study", Liver Transpl, 23, pp.999~1006 (2017)
  460. Yang JD, "A comparative study of postoperative outcomes between minimally invasive living donor hepatectomy and open living donor hepatectomy : the Korean organ transplantation registry", Surgery, 170, pp.271~276 (2021)
  461. Rho SY, "Outcomes of robotic living donor right hepatectomy from 52consecutive cases : comparison with open and laparoscopyassisted donor hepatectomy", Ann Surg, 275, pp.e433~e442 (2022)
  462. Chan SC, "Perpetuating proficiency in donor right hepatectomy for living donor liver transplantation", Asian J Surg, 37, pp.65~72 (2014)
  463. Ghobrial RM, "Donor morbidity after living donation for liver transplantation", Gastroenterology, 135, pp.468~476 (2008)
  464. Mark Siegler, "Recipient deaths during donor surgery: A new ethical problem in living donor liver transplantation (LDLT)", Liver Transplantation, 12(3), pp.358~360 (2006), Ovid Technologies (Wolters Kluwer Health)[DOI]
  465. Brown RS Jr, "Live donors in liver transplantation", Gastroenterology, 134, pp.1802~1813 (2008)
  466. Choi JY, "Outcomes of living liver donors are worse than those of matched healthy controls", J Hepatol, 76, pp.628~638 (2022)
  467. Schwartz M, "How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?", J Hepatol, 43, pp.584~589 (2005)
  468. Liang W, "Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma : a meta-analysis", Liver Transpl, 18, pp.62~69 (2012)
  469. Incheon Kang, "Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.589~602 (2021), 대한간학회[DOI]
  470. Lee SG, "Efficacy and safety of everolimus with reduced tacrolimus in liver transplant recipients : 24-month results from the pooled analysis of 2 randomized controlled trials", Transplantation, 105, pp.1564~1575 (2021)
  471. Yan X, "Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma : a systematic review and metaanalysis", Liver Transpl, 28, pp.1063~1077 (2022)
  472. Roayaie S, "Recurrence of hepatocellular carcinoma after liver transplant : patterns and prognosis", Liver Transpl, 10, pp.534~540 (2004)
  473. Hollebecque A, "Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation", Gastroenterol Clin Biol, 33, pp.361~369 (2009)
  474. Kim YS, "Recurrence of hepatocellular carcinoma after liver transplantation : patterns and prognostic factors based on clinical and radiologic features", AJR Am J Roentgenol, 189, pp.352~358 (2007)
  475. Bodzin AS, "Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation : impact of treatment modality and recurrence characteristics", Ann Surg, 266, pp.118~125 (2017)
  476. Roh YN, "The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation", Clin Transplant, 28, pp.141~148 (2014)
  477. Sapisochin G, "Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series", Ann Surg Oncol, 22, pp.2286~2294 (2015)
  478. Taketomi A, "Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation", Ann Surg Oncol, 17, pp.2283~2289 (2010)
  479. Huang J, "Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?", J Surg Res, 200, pp.122~130 (2016)
  480. Zhou B, "Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation", J Vasc Interv Radiol, 21, pp.333~338 (2010)
  481. Cheng YC, "Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation", Ann Transplant, 19, pp.309~316 (2014)
  482. Sposito C, "Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation : a case-control study", J Hepatol, 59, pp.59~66 (2013)
  483. Staufer K, "High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation", Transpl Int, 25, pp.1158~1164 (2012)
  484. Bhoori S, "Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation : a proof of principle", J Hepatol, 52, pp.771~775 (2010)
  485. Invernizzi F, "Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation", Transplantation, 104, pp.568~574 (2020)
  486. Waghray A, "Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation", Clin Transplant, 27, pp.555~561 (2013)
  487. Iavarone M, "Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation", Am J Transplant, 19, pp.3176~3184 (2019)
  488. Iavarone M, "Regorafenib efficacy after sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation : a retrospective study", Liver Transpl, 27, pp.1767~1778 (2021)
  489. Gassmann D, "Liver allograft failure after nivolumab treatment-a case report with systematic literature research", Transplant Direct, 4, pp.e376~ (2018)
  490. DeLeon TT, "Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation : the mayo clinic experience", J Gastrointest Oncol, 9, pp.1054~1062 (2018)
  491. Biondani P, "Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient", Ann Oncol, 29, pp.286~287 (2018)
  492. Patel IJ, "Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous imageguided interventions-part II : recommendations : endorsed by the Canadian association for interventional radiology and the cardiovascular and interventional radiological society of Europe", J Vasc Interv Radiol, 30, pp.1168~1184 (2019)
  493. Tripodi A, "Changing concepts of cirrhotic coagulopathy", Am J Gastroenterol, 112, pp.274~281 (2017)
  494. Lencioni R, "Early-stage hepatocellular carcinoma in patients with cirrhosis : long-term results of percutaneous image-guided radiofrequency ablation", Radiology, 234, pp.961~967 (2005)
  495. Lin SM, "Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm", Gastroenterology, 127, pp.1714~1723 (2004)
  496. Shiina S, "A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma", Gastroenterology, 129, pp.122~130 (2005)
  497. Lencioni RA, "Small hepatocellular carcinoma in cirrhosis : randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection", Radiology, 228, pp.235~240 (2003)
  498. Shiina S, "Radiofrequency ablation for hepatocellular carcinoma : 10-year outcome and prognostic factors", Am J Gastroenterol, 107, pp.569~577 (2012)[DOI]
  499. Livraghi T, "Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis : is resection still the treatment of choice?", Hepatology, 47, pp.82~89 (2008)
  500. Lee DH, "Laparoscopic liver resection versus percutaneous radiofrequency ablation for small single nodular hepatocellular carcinoma : comparison of treatment outcomes", Liver Cancer, 10, pp.25~37 (2021)
  501. Lee MW, "Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm : emphasis on association of local tumor progression and overall survival", Eur Radiol, 30, pp.2391~2400 (2020)
  502. Song KD, "Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm", World J Gastrointest Oncol, 11, pp.227~237 (2019)
  503. Kang TW, "Aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation : risk factors and clinical significance", Radiology, 276, pp.274~285 (2015)
  504. Lee S, "Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma : propensity score analyses of long-term outcomes", J Hepatol, 69, pp.70~78 (2018)
  505. Sohn W, "Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma", Oncotarget, 7, pp.47794~47807 (2016)
  506. Lee DH, "Nonhypervascular hepatobiliary phase hypointense nodules on gadoxetic acid-enhanced MRI : risk of HCC recurrence after radiofrequency ablation", J Hepatol, 62, pp.1122~1130 (2015)
  507. Park SJ, "Switching monopolar no-touch radiofrequency ablation using octopus electrodes for small hepatocellular carcinoma : a randomized clinical trial", Liver Cancer, 10, pp.72~81 (2021)
  508. Suh Yun Seok, "No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study", Korean Journal of Radiology, 22(12), pp.1974~1984 (2021), 대한영상의학회[DOI]
  509. Lee DH, "Outcome of no-touch radiofrequency ablation for small hepatocellular carcinoma : a multicenter clinical trial", Radiology, 301, pp.229~236 (2021)
  510. Majumdar A, "Management of people with earlyor very early-stage hepatocellular carcinoma : an attempted network meta-analysis", Cochrane Database Syst Rev (2017)
  511. Ng KKC, "Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma", Br J Surg, 104, pp.1775~1784 (2017)
  512. Chen MS, "A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma", Ann Surg, 243, pp.321~328 (2006)
  513. Feng K, "A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma", J Hepatol, 57, pp.794~802 (2012)
  514. Huang J, "A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria", Ann Surg, 252, pp.903~912 (2010)
  515. Wang Q, "Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria : a meta-analysis", ANZ J Surg, 91, pp.E432~E438 (2021)
  516. Hae Won Lee, "A prospective randomized study comparing radiofrequency ablation and hepatic resection for hepatocellular carcinoma", Annals of Surgical Treatment and Research, 94(2), pp.74~82 (2018), 대한외과학회
  517. Yang HJ, "Small single-nodule hepatocellular carcinoma : comparison of transarterial chemoembolization, radiofrequency ablation, and hepatic resection by using inverse probability weighting", Radiology, 271, pp.909~918 (2014)
  518. Kang TW, "Small hepatocellular carcinoma : radiofrequency ablation versus nonanatomic resection--propensity score analyses of long-term outcomes", Radiology, 275, pp.908~919 (2015)
  519. Kim GA, "Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas", Br J Surg, 103, pp.126~135 (2016)
  520. Qi X, "Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma : a meta-analysis of randomized controlled trials", J Clin Gastroenterol, 48, pp.450~457 (2014)
  521. Imai K, "Microvascular invasion in small-sized hepatocellular carcinoma : significance for outcomes following hepatectomy and radiofrequency ablation", Anticancer Res, 38, pp.1053~1060 (2018)
  522. Bai S, "Preoperative estimated risk of microvascular invasion is associated with prognostic differences following liver resection versus radiofrequency ablation for early hepatitis B virus-related hepatocellular carcinoma", Ann Surg Oncol, 28, pp.8174~8185 (2021)
  523. Shibata T, "Small hepatocellular carcinoma : is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment?", Radiology, 252, pp.905~913 (2009)
  524. Morimoto M, "Midterm outcomes in patients with intermediatesized hepatocellular carcinoma : a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization", Cancer, 116, pp.5452~5460 (2010)
  525. Peng ZW, "Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma : a prospective randomized trial", J Clin Oncol, 31, pp.426~432 (2013)
  526. Lu Z, "Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma : a meta-analysis of randomized-controlled trials", Eur J Gastroenterol Hepatol, 25, pp.187~194 (2013)
  527. Xin Wang, "Efficacy and Safety of Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinomas Compared with Radiofrequency Ablation Alone: A Time-to-Event Meta-Analysis", Korean Journal of Radiology, 17(1), pp.93~102 (2016), 대한영상의학회[DOI]
  528. Ni JY, "Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma", World J Gastroenterol, 19, pp.3872~3882 (2013)
  529. de Baère T, "Adverse events during radiofrequency treatment of 582hepatic tumors", AJR Am J Roentgenol, 181, pp.695~700 (2003)
  530. Rhim H, "Major complications after radio-frequency thermal ablation of hepatic tumors : spectrum of imaging findings", Radiographics, 23, pp.123~134 (2003)[DOI]
  531. Song I, "Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites : safety and technical efficacy in 143 patients", Eur Radiol, 19, pp.2630~2640 (2009)
  532. Ahn SJ, "Realtime US-CT", MR fusion imaging for percutaneous radiofrequency ablation of hepatocellular carcinoma, 2017, pp.66, 347~354
  533. Calandri M, "Fusion imaging and virtual navigation to guide percutaneous thermal ablation of hepatocellular carcinoma : a review of the literature", Cardiovasc Intervent Radiol, 42, pp.639~647 (2019)
  534. Lin SM, "Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less", Gut, 54, pp.1151~1156 (2005)
  535. Ishii H, "Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection", Cancer, 77, pp.1792~1796 (1996)
  536. Vilana R, "Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma", Hepatology, 16, pp.353~357 (1992)
  537. Livraghi T, "Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207patients", Cancer, 69, pp.925~929 (1992)
  538. Khan KN, "Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection", J Hepatol, 32, pp.269~278 (2000)
  539. Brunello F, "Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma : a randomized controlled trial", Scand J Gastroenterol, 43, pp.727~735 (2008)
  540. Giorgio A, "Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients : an Italian randomized controlled trial", Anticancer research, 31, pp.2291~2295 (2011)
  541. Cho YK, "Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies", Hepatology, 49, pp.453~459 (2009)
  542. Shen A, "Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm", J Gastroenterol Hepatol, 28, pp.793~800 (2013)
  543. Yang B, "Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma : a meta-analysis of randomized controlled trials", World J Surg Oncol, 13, pp.96~ (2015)
  544. Luo W, "Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas : a systematic review and metaanalysis", World J Surg Oncol, 15, pp.126~ (2017)
  545. Ebara M, "Percutaneous ethanol injection for small hepatocellular carcinoma : therapeutic efficacy based on 20-year observation", J Hepatol, 43, pp.458~464 (2005)
  546. 차동익, "Therapeutic Efficacy and Safety of Percutaneous Ethanol Injection with or without Combined Radiofrequency Ablation for Hepatocellular Carcinomas in High Risk Locations", Korean Journal of Radiology, 14(2), pp.240~247 (2013), 대한영상의학회[DOI]
  547. Lencioni R, "Percutaneous ethanol injection for hepatocellular carcinoma : alive or dead?", J Hepatol, 43, pp.377~380 (2005)
  548. Ahmed M, "Principles of and advances in percutaneous ablation", Radiology, 258, pp.351~369 (2011)
  549. Shi Y, "A recent advance in image-guided locoregional therapy for hepatocellular carcinoma", Gastrointest Tumors, 3, pp.90~102 (2016)
  550. Vietti Violi N, "Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease : a randomised controlled phase 2 trial", Lancet Gastroenterol Hepatol, 3, pp.317~325 (2018)
  551. Chong CCN, "Prospective double-blinded randomized controlled trial of microwave versus radiofrequency ablation for hepatocellular carcinoma(McRFA trial)", HPB(Oxford), 22, pp.1121~1127 (2020)
  552. Gupta P, "Overall survival and local recurrence following RFA, MWA, and cryoablation of very early and early HCC : a systematic review and bayesian network meta-analysis", Eur Radiol, 31, pp.5400~5408 (2021)
  553. Tan W, "Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma : a systematic review and meta-analysis", Int J Hyperthermia, 36, pp.264~272 (2019)
  554. Qian Yu, "Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials", Abdominal Radiology (2021), Springer Science and Business Media LLC[DOI]
  555. Zaitoun MMA, "Combined therapy with conventional trans-arterial chemoembolization(cTACE)and microwave ablation(MWA)for hepatocellular carcinoma >3-<5 cm", Int J Hyperthermia, 38, pp.248~256 (2021)
  556. Wang C, "Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma", Hepatology, 61, pp.1579~1590 (2015)
  557. Kim R, "Percutaneous cryoablation for perivascular hepatocellular carcinoma : therapeutic efficacy and vascular complications", Eur Radiol, 29, pp.654~662 (2019)
  558. Ko SE, "Comparison of procedure-related complications between percutaneous cryoablation and radiofrequency ablation for treating periductal hepatocellular carcinoma", Int J Hyperthermia, 37, pp.1354~1361 (2020)
  559. Zhou Y, "Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma", BMC Gastroenterol, 10, pp.78~ (2010)
  560. Lee DH, "Radiofrequency ablation of hepatocellular carcinoma as first-line treatment : long-term results and prognostic factors in 162patients with cirrhosis", Radiology, 270, pp.900~909 (2014)
  561. Rossi S, "Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas : a long-term cohort study", Hepatology, 53, pp.136~147 (2011)
  562. Imai K, "Salvage treatment for local recurrence of hepatocellular carcinoma after local ablation therapy", Hepatol Res, 44, pp.E335~E345 (2014)
  563. Xie X, "Local recurrence after radiofrequency ablation of hepatocellular carcinoma : treatment choice and outcome", J Gastrointest Surg, 19, pp.1466~1475 (2015)
  564. Okuwaki Y, "Repeat radiofrequency ablation provides survival benefit in patients with intrahepatic distant recurrence of hepatocellular carcinoma", Am J Gastroenterol, 104, pp.2747~2753 (2009)
  565. Sotiropoulos GC, "Resectability of hepatocellular carcinoma : evaluation of 333 consecutive cases at a single hepatobiliary specialty center and systematic review of the literature", Hepatogastroenterology, 53, pp.322~329 (2006)
  566. Kwak HW, "Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus-endemic area", J Gastroenterol Hepatol, 29, pp.820~829 (2014)
  567. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE study", Liver Int, 35, pp.2155~2166 (2015)
  568. Matsui O, "Small hepatocellular carcinoma : treatment with subsegmental transcatheter arterial embolization", Radiology, 188, pp.79~83 (1993)
  569. Miyayama S, "Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas : relationship between local tumor recurrence and visualization of the portal vein with iodized oil", J Vasc Interv Radiol, 18, pp.365~376 (2007)
  570. Golfieri R, "Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small(<5 cm)hepatocellular carcinomas", Hepatology, 53, pp.1580~1589 (2011)
  571. Yamakado K, "Hepatic arterial embolization for unresectable hepatocellular carcinomas : do technical factors affect prognosis?", Jpn J Radiol, 30, pp.560~566 (2012)
  572. Golfieri R, "Hepatocellular carcinoma responding to superselective transarterial chemoembolization : an issue of nodule dimension?", J Vasc Interv Radiol, 24, pp.509~517 (2013)
  573. Iwazawa J, "Survival after C-arm CT-assisted chemoembolization of unresectable hepatocellular carcinoma", Eur J Radiol, 81, pp.3985~3992 (2012)
  574. Miyayama S, "Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≤6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography", Cardiovasc Intervent Radiol, 37, pp.388~395 (2014)
  575. Pung L, "The role of cone-beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma : a systematic review and meta-analysis", J Vasc Interv Radiol, 28, pp.334~341 (2017)
  576. Wattanasatesiri T, "Cone-beam CT-guided chemoembolization in patients with complete response after previous chemoembolization but subsequent elevated α-fetoprotein without overt hepatocellular carcinoma", J Vasc Interv Radiol, 30, pp.1273~1280 (2019)
  577. Young S, "Current trends in the treatment of hepatocellular carcinoma with transarterial embolization : a cross-sectional survey of techniques", Eur Radiol, 29, pp.3287~3295 (2019)
  578. Ikeda M, "Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma : a phase III randomized trial", J Gastroenterol, 53, pp.281~290 (2018)
  579. Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
  580. Lo CM, "Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma", Hepatology, 35, pp.1164~1171 (2002)
  581. Takayasu K, "Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients", Gastroenterology, 131, pp.461~469 (2006)
  582. Takayasu K, "Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines", J Hepatol, 56, pp.886~892 (2012)
  583. Lencioni R, "Lipiodol transarterial chemoembolization for hepatocellular carcinoma : a systematic review of efficacy and safety data", Hepatology, 64, pp.106~116 (2016)
  584. Ikeda M, "Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma : an Asian cooperative study between Japan and Korea", J Vasc Interv Radiol, 24, pp.490~500 (2013)
  585. Lee HS, "Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area : a prospective cohort study", J Clin Oncol, 20, pp.4459~4465 (2002)
  586. Bargellini I, "Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment : a prospective cohort study", Eur J Radiol, 81, pp.1173~1178 (2012)
  587. Joo Hyun Oh, "Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria", Annals of Surgical Treatment and Research, 99(4), pp.238~246 (2020), 대한외과학회[DOI]
  588. Yun BY, "Prognosis of early-stage hepatocellular carcinoma: comparison between trans-arterial chemoembolization and radiofrequency ablation", Cancers(Basel), 12, pp.2527~ (2020)
  589. Sinn DH, "Patterns and outcomes in hepatocellular carcinoma patients with portal vein invasion : a multicenter prospective cohort study", Dig Dis Sci, 66, pp.315~324 (2021)
  590. Chung JW, "Hepatocellular carcinoma and portal vein invasion : results of treatment with transcatheter oily chemoembolization", AJR Am J Roentgenol, 165, pp.315~321 (1995)
  591. Lee HS, "The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study", Cancer, 79, pp.2087~2094 (1997)
  592. Georgiades CS, "Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis", J Vasc Interv Radiol, 16, pp.1653~1659 (2005)
  593. Chung GE, "Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival", Radiology, 258, pp.627~634 (2011)
  594. Silva JP, "Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis", HPB(Oxford), 19, pp.659~666 (2017)
  595. Luo J, "Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study", Ann Surg Oncol, 18, pp.413~420 (2011)
  596. Niu ZJ, "Transarterial chemoembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus : using a new classification", Med Oncol, 29, pp.2992~2997 (2012)
  597. Xue TC, "Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus : a meta-analysis", BMC Gastroenterol, 13, pp.60~ (2013)
  598. Choi JW, "Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus", Eur Radiol, 27, pp.1448~1458 (2017)
  599. Cho JY, "The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma", Liver Int, 34, pp.795~801 (2014)
  600. Kim GA, "Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis : a propensity score analysis", J Vasc Interv Radiol, 26, pp.320~329 (2015)
  601. Yoon SM, "Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : a randomized clinical trial", JAMA Oncol, 4, pp.661~669 (2018)
  602. Yoo DJ, "Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma : does transarterial chemoembolization improve survival in these patients?", J Gastroenterol Hepatol, 26, pp.145~154 (2011)
  603. Jung SM, "Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases", J Gastroenterol Hepatol, 27, pp.684~689 (2012)
  604. Kim J, "Hepatocellular carcinoma with extrahepatic metastasis : are there still candidates for transarterial chemoembolization as an initial treatment", PLoS One, 14, pp.e0213547~ (2019)
  605. Dai Y, "Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma : a metaanalysis", Transl Oncol, 14, pp.101238~ (2021)
  606. Kudo M, "Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial", Gut, 69, pp.1492~1501 (2020)
  607. Fu Z, "Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma(uHCC) : a retrospective controlled study", Hepatol Int, 15, pp.663~675 (2021)
  608. Chung JW, "Hepatic tumors : predisposing factors for complications of transcatheter oily chemoembolization", Radiology, 198, pp.33~40 (1996)
  609. Ogasawara S, "A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization", Hepatology, 67, pp.575~585 (2018)
  610. Yang H, "Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma : a randomized, double-blinded, placebocontrolled study", J Vasc Interv Radiol, 28, pp.1503~1511 (2017)
  611. Lv N, "Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma : a prospective randomized trial", Eur Radiol, 26, pp.3492~3499 (2016)
  612. Varela M, "Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics", J Hepatol, 46, pp.474~481 (2007)
  613. Lammer J, "Prospective randomized study of doxorubicin-elutingbead embolization in the treatment of hepatocellular carcinoma : results of the PRECISION V study", Cardiovasc Intervent Radiol, 33, pp.41~52 (2010)
  614. Sacco R, "Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 22, pp.1545~1552 (2011)
  615. Golfieri R, "Randomised controlled trial of doxorubicineluting beads vs conventional chemoembolisation for hepatocellular carcinoma", Br J Cancer, 111, pp.255~264 (2014)
  616. Malagari K, "Chemoembolization with doxorubicineluting beads for unresectable hepatocellular carcinoma : five-year survival analysis", Cardiovasc Intervent Radiol, 35, pp.1119~1128 (2012)
  617. Lee M, "Korean multicenter registry of transcatheter arterial chemoembolization with drug-eluting embolic agents for nodular hepatocellular carcinomas : six-month outcome analysis", J Vasc Interv Radiol, 28, pp.502~512 (2017)
  618. Lee Myungsu, "Prospective Multi-Center Korean Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolics for Nodular Hepatocellular Carcinoma: A Two-Year Outcome Analysis", Korean Journal of Radiology, 22(10), pp.1658~1670 (2021), 대한영상의학회[DOI]
  619. Lee IJ, "Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in child-pugh class A patients", Ther Adv Med Oncol, 11, pp.1758835919866072~ (2019)
  620. Deipolyi AR, "Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 26, pp.516~522 (2015)
  621. Urbano J, "Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma", Eur J Radiol, 126, pp.108966~ (2020)
  622. Vogl TJ, "Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads : results from the PRECISION V randomized trial", AJR Am J Roentgenol, 197, pp.W562~W570 (2011)
  623. Monier A, "Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma : comparison between drug-eluting beads and lipiodol emulsion", Eur Radiol, 27, pp.1431~1439 (2017)
  624. Salem R, "Radioembolization with 90Yttrium microspheres : a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1 : technical and methodologic considerations", J Vasc Interv Radiol, 17, pp.1251~1278 (2006)
  625. Gabr A, "Streamlining radioembolization in UNOS T1", T2 hepatocellular carcinoma by eliminating lung shunt estimation, 2020, pp.72, 1151~1158
  626. Mazzaferro V, "Yttrium-90 radioembolization for intermediateadvanced hepatocellular carcinoma : a phase 2 study", Hepatology, 57, pp.1826~1837 (2013)
  627. Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
  628. Sangro B, "Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages : a European evaluation", Hepatology, 54, pp.868~878 (2011)
  629. Hilgard P, "Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma : European experience on safety and long-term survival", Hepatology, 52, pp.1741~1179 (2010)
  630. Kolligs FT, "Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma", Liver Int, 35, pp.1715~1721 (2015)
  631. Pitton MB, "Randomized comparison of selective internal radiotherapy(SIRT)versus drug-eluting bead transarterial chemoembolization(DEB-TACE)for the treatment of hepatocellular carcinoma", Cardiovasc Intervent Radiol, 38, pp.352~360 (2015)
  632. Salem R, "Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma", Gastroenterology, 151, pp.1155~1163 (2016)
  633. Casadei Gardini A, "Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma : a meta-analysis of randomized trials", Onco Targets Ther, 11, pp.7315~7321 (2018)
  634. Chow PKH, "SIRveNIB : selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma", J Clin Oncol, 36, pp.1913~1921 (2018)
  635. Vilgrain V, "Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma(SARAH) : an open-label randomised controlled phase 3 trial", Lancet Oncol, 18, pp.1624~1636 (2017)
  636. Ricke J, "Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma", J Hepatol, 71, pp.1164~1174 (2019)
  637. Garin E, "Boosted selective internal radiation therapy with 90Y-loaded glass microspheres(B-SIRT)for hepatocellular carcinoma patients : a new personalized promising concept", Eur J Nucl Med Mol Imaging, 40, pp.1057~1068 (2013)
  638. Salem R, "Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC : the LEGACY study", Hepatology, 74, pp.2342~2352 (2021)
  639. Garin E, "Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma(DOSISPHERE-01) : a randomised, multicentre, open-label phase 2 trial", Lancet Gastroenterol Hepatol, 6, pp.17~29 (2021)
  640. Kim HC, "Feasibility of boosted radioembolization for hepatocellular carcinoma larger than 5 cm", J Vasc Interv Radiol, 30, pp.1~8 (2019)
  641. Kim J, "Longterm outcomes of transarterial radioembolization for large single hepatocellular carcinoma : a comparison to resection", J Nucl Med, 63, pp.1215~1222 (2022)
  642. BenguerfiS, "Selective internal radiation therapy in older patients with hepatocellular carcinoma : a retrospective analysis", Eur J Gastroenterol Hepatol, 34, pp.417~421 (2022)
  643. Das A, "Contemporary systematic review of health-related quality of life outcomes in locoregional therapies for hepatocellular carcinoma", J Vasc Interv Radiol, 30, pp.1924~1933 (2019)
  644. Sangro B, "Liver disease induced by radioembolization of liver tumors : description and possible risk factors", Cancer, 112, pp.1538~1546 (2008)
  645. Gil-Alzugaray B, "Prognostic factors and prevention of radioembolization-induced liver disease", Hepatology, 57, pp.1078~1087 (2013)
  646. Sangro B, "Prevention and treatment of complications of selective internal radiation therapy : expert guidance and systematic review", Hepatology, 66, pp.969~982 (2017)
  647. Currie BM, "Radioembolization-induced chronic hepatotoxicity: a singlecenter cohort analysis", J Vasc Interv Radiol, 30, pp.1915~1923 (2019)
  648. Kudo M, "Management of hepatocellular carcinoma in Japan : JSH consensus statements and recommendations 2021 update", Liver Cancer, 10, pp.181~223 (2021)
  649. Vogl TJ, "Transarterial chemoembolization for hepatocellular carcinoma : volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center", Radiology, 214, pp.349~357 (2000)
  650. Lencioni R, "Loco-regional treatment of hepatocellular carcinoma", Hepatology, 52, pp.762~773 (2010)
  651. Yamanaka K, "Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma", J Gastroenterol, 47, pp.343~346 (2012)
  652. Park JW, "Consensus recommendations and review by an international expert panel on interventions in hepatocellular carcinoma(EPOIHCC)", Liver Int, 33, pp.327~337 (2013)
  653. Kim HY, "Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma", J Gastroenterol Hepatol, 27, pp.1051~1056 (2012)
  654. Sieghart W, "The ART of decision making : retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma", Hepatology, 57, pp.2261~2273 (2013)
  655. Adhoute X, "Retreatment with TACE : the ABCR SCORE, an aid to the decision-making process", J Hepatol, 62, pp.855~862 (2015)
  656. Yoon JS, "Tumor marker-based definition of the transarterial chemoembolization-refractoriness in intermediate-stage hepatocellular carcinoma: a multi-cohort study", Cancers(Basel), 11, pp.1721~ (2019)
  657. Kim BK, "Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization : development of a prediction model", Liver Int, 36, pp.92~99 (2016)
  658. Kim JH, "Novel albumin-bilirubin grade-based risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization", Dig Dis Sci, 63, pp.1062~1071 (2018)
  659. Kudo M, "Transarterial chemoembolization failure", refractoriness : JSH-LCSGJ criteria 2014 update, 2014, pp.87(Suppl 1), 22~31
  660. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 20(7), pp.1042~1113 (2019), 대한영상의학회[DOI]
  661. Bruix J, "Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma : subanalyses of a phase III trial", J Hepatol, 57, pp.821~829 (2012)
  662. Ogasawara S, "Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization", Oncology, 87, pp.330~341 (2014)
  663. Arizumi T, "Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization(TACE)refractory and intermediate-stage hepatocellular carcinoma", Liver Cancer, 4, pp.253~262 (2015)
  664. Takaki H, "Hepatic arterial infusion chemotherapy with fine-powder cisplatin and iodized-oil suspension in patients with intermediate-stage and advanced-stage(Barcelona clinic liver cancer stage-B or stage-C)hepatocellular carcinoma : multicenter phase-II clinical study", Int J Clin Oncol, 20, pp.745~754 (2015)
  665. Lin J, "Combination treatment including targeted therapy for advanced hepatocellular carcinoma", Oncotarget, 7, pp.71036~71051 (2016)
  666. Kim HY, "Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma : past, present, and future", Liver Cancer, 3, pp.9~17 (2014)
  667. Liu L, "Combination therapy of sorafenib and TACE for unresectable HCC : a systematic review and meta-analysis", PLoS One, 9, pp.e91124~ (2014)
  668. Lencioni R, "Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC : the SPACE trial", J Hepatol, 64, pp.1090~1098 (2016)
  669. Meyer T, "Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma(TACE 2) : a randomised placebo-controlled, double-blind, phase 3 trial", Lancet Gastroenterol Hepatol, 2, pp.565~575 (2017)
  670. Kudo M, "Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma(ORIENTAL) : a randomised, doubleblind, placebo-controlled, multicentre, phase 3 study", Lancet Gastroenterol Hepatol, 3, pp.37~46 (2018)
  671. Korean Liver Cancer Study Group, "2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma", Korean Journal of Radiology, 16(3), pp.465~522 (2015), 대한영상의학회[DOI]
  672. Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC, "2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma", Gut and Liver, 13(3), pp.227~299 (2019), 거트앤리버 소화기연관학회협의회[DOI]
  673. Seo Hee Choi, "Strategic application of radiotherapy for hepatocellular carcinoma", Clinical and Molecular Hepatology, 24(2), pp.114~134 (2018), 대한간학회
  674. Park HC, "Consensus for radiotherapy in hepatocellular carcinoma from the 5th Asia-Pacific primary liver cancer expert meeting(APPLE 2014) : current practice and future clinical trials", Liver Cancer, 5, pp.162~174 (2016)
  675. Kim TH, "Dosevolumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy", Int J Radiat Oncol Biol Phys, 67, pp.225~231 (2007)
  676. Schefter TE, "A phase I trial of stereotactic body radiation therapy(SBRT)for liver metastases", Int J Radiat Oncol Biol Phys, 62, pp.1371~1378 (2005)
  677. Pan CC, "Radiation-associated liver injury", Int J Radiat Oncol Biol Phys, 76, pp.S94~S100 (2010)
  678. Kimura T, "A multi-institutional retrospective study of repeated stereotactic body radiation therapy for intrahepatic recurrent hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 108, pp.1265~1275 (2020)
  679. McDuffSGR, "Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis", Pract Radiat Oncol, 8, pp.414~421 (2018)
  680. Oshiro Y, "Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma", Radiother Oncol, 123, pp.240~245 (2017)
  681. 배선현, "Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma", Journal of Korean Medical Science, 28(2), pp.213~219 (2013), 대한의학회
  682. Andolino DL, "Stereotactic body radiotherapy for primary hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 81, pp.e447~e453 (2011)
  683. Honda Y, "Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma", J Gastroenterol Hepatol, 28, pp.530~536 (2013)
  684. Sanuki N, "Stereotactic body radiotherapy for small hepatocellular carcinoma : a retrospective outcome analysis in 185 patients", Acta Oncol, 53, pp.399~404 (2014)
  685. Yoon SM, "Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma", PLoS One, 8, pp.e79854~ (2013)
  686. Xi M, "Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and", or inferior vena cava tumor thrombosis, 2013, pp.8, e63864~
  687. Weiner AA, "Stereotactic body radiotherapy for primary hepatic malignancies-report of a phase I", II institutional study, 2016, pp.121, 79~85
  688. Takeda A, "Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation", Cancer, 122, pp.2041~2049 (2016)
  689. Wahl DR, "Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma", J Clin Oncol, 34, pp.452~459 (2016)
  690. Kawashima M, "Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma", J Clin Oncol, 23, pp.1839~1846 (2005)
  691. Fukumitsu N, "A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 74, pp.831~836 (2009)
  692. Sugahara S, "Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis", Strahlenther Onkol, 185, pp.782~788 (2009)
  693. Nakayama H, "Proton beam therapy for hepatocellular carcinoma : the University of Tsukuba experience", Cancer, 115, pp.5499~5506 (2009)
  694. Komatsu S, "Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma", Cancer, 117, pp.4890~4904 (2011)
  695. Bush DA, "The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma : a phase 2 prospective trial", Cancer, 117, pp.3053~3059 (2011)
  696. 김태현, "Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma", Cancer Research and Treatment, 47(1), pp.34~45 (2015), 대한암학회[DOI]
  697. Hong TS, "Multi-institutional phase II study of highdose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Clin Oncol, 34, pp.460~468 (2016)
  698. Bush DA, "Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma : results of an interim analysis", Int J Radiat Oncol Biol Phys, 95, pp.477~482 (2016)
  699. Kasuya G, "Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma : combined analyses of 2 prospective trials", Cancer, 123, pp.3955~3965 (2017)
  700. Fukuda K, "Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma", Cancer Sci, 108, pp.497~503 (2017)
  701. Feng M, "Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage : a phase 2 clinical trial", JAMA Oncol, 4, pp.40~47 (2018)
  702. Kim JW, "Phase I", II trial of helical IMRT-based stereotactic body radiotherapy for hepatocellular carcinoma, 2019, pp.51, 445~451
  703. Jang WI, "A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma : safety and efficacy", Cancer, 126, pp.363~372 (2020)
  704. Durand-Labrunie J, "Curative irradiation treatment of hepatocellular carcinoma : a multicenter phase 2 trial", Int J Radiat Oncol Biol Phys, 107, pp.116~125 (2020)
  705. Beaton L, "Stereotactic body radiotherapy for large unresectable hepatocellular carcinomas-a single institution phase II study", Clin Oncol(R Coll Radiol), 32, pp.423~432 (2020)
  706. Sang Min Yoon, "Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial", Clinical and Molecular Hepatology, 26(4), pp.506~515 (2020), 대한간학회[DOI]
  707. Kimura T, "Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma : the STRSPH study", Hepatol Res, 51, pp.461~471 (2021)
  708. Brunner TB, "Efficacy of stereotactic body radiotherapy in patients with hepatocellular carcinoma not suitable for transarterial chemoembolization(HERACLES : HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)", Front Oncol, 11, pp.653141~ (2021)
  709. Kim TH, "Phase II study of hypofractionated proton beam therapy for hepatocellular carcinoma", Front Oncol, 10, pp.542~ (2020)
  710. Parzen JS, "Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors : multi-institutional prospective results from the Proton collaborative group", Radiat Oncol, 15, pp.255~ (2020)
  711. Iwata H, "A phase 2 study of image-guided proton therapy for operable or ablation-treatable primary hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 111, pp.117~126 (2021)
  712. Huo YR, "Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma : a systematic review and metaanalysis", JAMA Oncol, 1, pp.756~765 (2015)
  713. Hsu HC, "Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma", Br J Radiol, 80, pp.38~42 (2007)
  714. Oh D, "Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization : a prospective evaluation of efficacy and toxicity", Am J Clin Oncol, 33, pp.370~375 (2010)
  715. Choi C, "A prospective phase 2 multicenter study for the efficacy of radiation therapy following incomplete transarterial chemoembolization in unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 90, pp.1051~1060 (2014)
  716. Jacob R, "Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥ 3 cm", HPB(Oxford), 17, pp.140~149 (2015)
  717. 유정일, "Scheduled Interval Trans-Catheter Arterial Chemoembolization Followed by Radiation Therapy in Patients with Unresectable Hepatocellular Carcinoma", Journal of Korean Medical Science, 27(7), pp.736~743 (2012), 대한의학회[DOI]
  718. Yamada K, "Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 57, pp.113~119 (2003)
  719. Kim DY, "Threedimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma", Cancer, 103, pp.2419~2246 (2005)
  720. Han KH, "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis", Cancer, 113, pp.995~1003 (2008)
  721. Shirai S, "Feasibility and efficacy of single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma 8 cm or more with portal vein tumor thrombus in combination with transcatheter arterial chemoembolization", Int J Radiat Oncol Biol Phys, 76, pp.1037~1044 (2010)
  722. Koo JE, "Combination of transarterial chemoembolization and threedimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus", Int J Radiat Oncol Biol Phys, 78, pp.180~187 (2010)
  723. 유정일, "Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy", Journal of Korean Medical Science, 26(8), pp.1014~1022 (2011), 대한의학회
  724. Chuma M, "Efficacy of therapy for advanced hepatocellular carcinoma : intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation", J Gastroenterol Hepatol, 26, pp.1123~1132 (2011)
  725. Yoon SM, "Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein : long-term patient outcomes", Int J Radiat Oncol Biol Phys, 82, pp.2004~2011 (2012)
  726. Hou JZ, "Influence of tumor thrombus location on the outcome of externalbeam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion", Int J Radiat Oncol Biol Phys, 84, pp.362~368 (2012)
  727. Park MS, "Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis", Cancer Chemother Pharmacol, 71, pp.165~173 (2013)
  728. Tanaka Y, "Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels : efficacy and outcomes", J Gastroenterol Hepatol, 29, pp.352~357 (2014)
  729. Lee SU, "Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Strahlenther Onkol, 190, pp.806~814 (2014)
  730. Kim DY, "Riskadapted simultaneous integrated boost-proton beam therapy(SIB-PBT)for advanced hepatocellular carcinoma with tumour vascular thrombosis", Radiother Oncol, 122, pp.122~129 (2017)
  731. Dutta D, "Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery : interim results of a prospective study", Indian J Gastroenterol, 40, pp.389~401 (2021)
  732. Kodama K, "Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis", Oncology, 94, pp.215~222 (2018)
  733. Kosaka Y, "Hepatic arterial infusion chemotherapy combined with radiation therapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk or bilobar of the portal vein", Liver Cancer, 10, pp.151~160 (2021)
  734. Lou J, "Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava", right atrium tumor thrombus : a multi-center analysis, 2019, pp.19, 668~
  735. Rim CH, "Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and", or right atrium involvement : a multicenter trial in Korea(KROG 17-10), 2020, pp.96, 759~766
  736. Rim CH, "External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and", or right atrium : a meta-analysis and systemic review, 2018, pp.129, 123~129
  737. Kim BK, "Efficacy and safety of liver-directed concurrent chemoradiotherapy and sequential sorafenib for advanced hepatocellular carcinoma : a prospective phase 2 trial", Int J Radiat Oncol Biol Phys, 107, pp.106~115 (2020)
  738. Im JH, "Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area", Liver Int, 37, pp.90~100 (2017)
  739. Zhao Q, "Comparison of intra-arterial chemoembolization with and without radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis : a meta-analysis", Ther Clin Risk Manag, 13, pp.21~31 (2016)
  740. Li MF, "Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion", Ther Clin Risk Manag, 14, pp.1157~1168 (2018)
  741. Nakazawa T, "Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis : propensity score analysis", BMC Gastroenterol, 14, pp.84~ (2014)
  742. Cho YY, "Clinical characteristics of long-term survivors after sorafenib treatment for unresectable hepatocellular carcinoma : a Korean national multicenter retrospective cohort study", J Hepatocell Carcinoma, 8, pp.613~623 (2021)
  743. Chu SS, "Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib : a nationwide cancer-registry-based study", Sci Rep, 11, pp.1614~ (2021)
  744. Chang WI, "Role of radiotherapy in Barcelona clinic liver cancer stage C hepatocellular carcinoma treated with sorafenib", J Gastroenterol Hepatol, 37, pp.387~394 (2022)
  745. Yu JI, "Clinical significance of radiotherapy before and", or during nivolumab treatment in hepatocellular carcinoma, 2019, pp.8, 6986~6994
  746. Zhong L, "Safety of PD-1", PD-L1 inhibitors combined with palliative radiotherapy and anti-angiogenic therapy in advanced hepatocellular carcinoma, 2021, pp.11, 686621~
  747. Chu HH, "Chemoembolization plus radiotherapy versus chemoembolization plus sorafenib for the treatment of hepatocellular carcinoma invading the portal vein: a propensity score matching analysis", Cancers(Basel), 12, pp.1116~ (2020)
  748. Lee HS, "Surgical resection after down-staging of locally advanced hepatocellular carcinoma by localized concurrent chemoradiotherapy", Ann Surg Oncol, 21, pp.3646~3653 (2014)
  749. Hamaoka M, "Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy : a retrospective cohort study", Int J Surg, 44, pp.223~228 (2017)
  750. Chong JU, "Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus", Ann Surg Oncol, 25, pp.3308~3315 (2018)
  751. 한광협, "Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy", Yonsei Medical Journal, 57(5), pp.1276~1281 (2016), 연세대학교의과대학[DOI]
  752. Choi JY, "The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus", Liver Transpl, 23, pp.545~551 (2017)
  753. Wei X, "Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus : a randomized, open-label, multicenter controlled study", J Clin Oncol, 37, pp.2141~2151 (2019)
  754. Katz AW, "Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma : clinical outcome and pathologic correlation", Int J Radiat Oncol Biol Phys, 83, pp.895~900 (2012)
  755. Mannina EM, "Role of stereotactic body radiation therapy before orthotopic liver transplantation : retrospective evaluation of pathologic response and outcomes", Int J Radiat Oncol Biol Phys, 97, pp.931~938 (2017)
  756. Wong TC, "Prospective study of stereotactic body radiation therapy for hepatocellular carcinoma on waitlist for liver transplant", Hepatology, 74, pp.2580~2594 (2021)
  757. Park W, "Local radiotherapy for patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 61, pp.1143~1150 (2005)
  758. Kim TH, "Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable", Am J Clin Oncol, 29, pp.568~575 (2006)
  759. Huang WY, "Stereotactic body radiation therapy in recurrent hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 84, pp.355~361 (2012)
  760. Seong J, "Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization", Int J Radiat Oncol Biol Phys, 47, pp.1331~1335 (2000)
  761. Bae SH, "Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 82, pp.e603~e607 (2012)
  762. 차혜정, "Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)", Cancer Research and Treatment, 49(1), pp.61~69 (2017), 대한암학회
  763. Soliman H, "Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases", J Clin Oncol, 31, pp.3980~3986 (2013)
  764. Yeung CSY, "Palliative liver radiotherapy(RT)for symptomatic hepatocellular carcinoma(HCC)", Sci Rep, 10, pp.1254~ (2020)
  765. Cheng SH, "A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma", J Gastroenterol Hepatol, 14, pp.1025~1033 (1999)
  766. Huang JF, "Incidence and clinical outcome of icteric type hepatocellular carcinoma", J Gastroenterol Hepatol, 17, pp.190~195 (2002)
  767. Sang Min Yoon, "Radioresponse of Hepatocellular Carcinoma-Treatment of Lymph Node Metastasis", Cancer Research and Treatment, 36(1), pp.79~84 (2004), 대한암학회
  768. Zeng ZC, "Consideration of role of radiotherapy for lymph node metastases in patients with HCC : retrospective analysis for prognostic factors from 125 patients", Int J Radiat Oncol Biol Phys, 63, pp.1067~1076 (2005)
  769. Park YJ, "Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma", J Gastroenterol, 41, pp.1099~1106 (2006)
  770. Yamashita H, "Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma : retrospective study", J Gastroenterol Hepatol, 22, pp.523~527 (2007)
  771. Jang JW, "Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases", Int J Radiat Oncol Biol Phys, 74, pp.412~418 (2009)
  772. Yeung R, "Institutional analysis of stereotactic body radiotherapy(SBRT)for oligometastatic lymph node metastases", Radiat Oncol, 12, pp.105~ (2017)
  773. Kim Y, "Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma : a multi-institutional retrospective study(KROG 15-02)", Oncotarget, 8, pp.94450~94461 (2017)
  774. Jung J, "Radiotherapy for adrenal metastasis from hepatocellular carcinoma : a multi-Institutional retrospective study(KROG 13-05)", PLoS One, 11, pp.e0152642~ (2016)
  775. Jiang W, "Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma", Clin Exp Metastasis, 29, pp.197~205 (2012)
  776. Seong J, "Radiotherapy for painful bone metastases from hepatocellular carcinoma", Liver Int, 25, pp.261~265 (2005)
  777. He J, "Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy", Cancer, 115, pp.2710~2720 (2009)
  778. Sakaguchi M, "Radiation therapy and palliative care prolongs the survival of hepatocellular carcinoma patients with bone metastases", Intern Med, 55, pp.1077~1083 (2016)
  779. Jung IH, "High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma", Oncotarget, 8, pp.15182~15192 (2017)
  780. Kim TH, "Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma", J Cancer Res Clin Oncol, 147, pp.2693~2700 (2021)
  781. Rades D, "Radiation therapy for metastatic spinal cord compression in patients with hepatocellular carcinoma", In Vivo, 29, pp.749~752 (2015)
  782. Choi HJ, "Brain metastases from hepatocellular carcinoma : prognostic factors and outcome : brain metastasis from HCC", J Neurooncol, 91, pp.307~313 (2009)
  783. Kim K, "Efficacy of local therapy for oligometastatic hepatocellular carcinoma : a propensity score matched analysis", J Hepatocell Carcinoma, 8, pp.35~44 (2021)
  784. Yoo C, "Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma : a multinational multicenter retrospective study", Liver Cancer, 10, pp.107~114 (2021)
  785. Kim N, "Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma", Radiother Oncol, 131, pp.81~87 (2019)
  786. Hara K, "Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation : a propensity score analysis", Hepatology, 69, pp.2533~2545 (2019)
  787. Kim N, "Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma", J Hepatol, 73, pp.121~129 (2020)
  788. Ueno M, "Stereotactic body radiation therapy versus radiofrequency ablation for single small hepatocellular carcinoma : a propensity-score matching analysis of their impact on liver function and clinical outcomes", J Gastrointest Oncol, 12, pp.2334~2344 (2021)
  789. Jeong Y, "Radiofrequency ablation versus stereotactic body radiation therapy for small(≤ 3 cm)hepatocellular carcinoma : a retrospective comparison analysis", J Gastroenterol Hepatol, 36, pp.1962~1970 (2021)
  790. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
  791. Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
  792. Cheng AL, "Sunitinib versus sorafenib in advanced hepatocellular cancer : results of a randomized phase III trial", J Clin Oncol, 31, pp.4067~4075 (2013)
  793. Johnson PJ, "Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma : results from the randomized phase III BRISK-FL study", J Clin Oncol, 31, pp.3517~3524 (2013)
  794. Cainap C, "Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma : results of a randomized phase III trial", J Clin Oncol, 33, pp.172~179 (2015)
  795. Zhu AX, "SEARCH : a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma", J Clin Oncol, 33, pp.559~566 (2015)
  796. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
  797. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
  798. Yau T, "Nivolumab versus sorafenib in advanced hepatocellular carcinoma(CheckMate 459) : a randomised, multicentre, openlabel, phase 3 trial", Lancet Oncol, 23, pp.77~90 (2022)
  799. Furuse J, "Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma", Cancer Sci, 99, pp.159~165 (2008)
  800. Shim JH, "Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a hepatitis B virus-endemic area", J Cancer Res Clin Oncol, 135, pp.617~625 (2009)
  801. Kim JE, "Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function", Cancer Chemother Pharmacol, 68, pp.1285~1290 (2011)
  802. Hollebecque A, "Safety and efficacy of sorafenib in hepatocellular carcinoma : the impact of the Child-Pugh score", Aliment Pharmacol Ther, 34, pp.1193~1201 (2011)
  803. Chiu J, "The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis : a retrospective analysis of efficacy, safety, and survival benefits", Cancer, 118, pp.5293~5301 (2012)
  804. Pressiani T, "Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma : a prospective feasibility analysis", Ann Oncol, 24, pp.406~411 (2013)
  805. Ogasawara S, "Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma : safety, efficacy and prognostic factors", Invest New Drugs, 33, pp.729~739 (2015)
  806. Suzuki E, "A multicenter phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class", Jpn J Clin Oncol, 48, pp.317~321 (2018)
  807. Kim HY, "Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma", J Gastroenterol Hepatol, 28, pp.1756~1761 (2013)
  808. Marrero JA, "Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups : the GIDEON study", J Hepatol, 65, pp.1140~1147 (2016)
  809. Brose MS, "Management of sorafenib-related adverse events : a clinician’s perspective", Semin Oncol (2014)
  810. Granito A, "Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib", Therap Adv Gastroenterol, 9, pp.240~249 (2016)
  811. Ren Z, "Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma", J Clin Oncol, 33, pp.894~900 (2015)
  812. Lee YS, "Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma : a multicenter, randomised, double-blind controlled study", Eur J Cancer, 140, pp.19~27 (2020)
  813. Evans TRJ, "Urine protein : creatinine ratio vs 24-hour urine protein for proteinuria management : analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma", Br J Cancer, 121, pp.218~221 (2019)
  814. Cho JY, "Cost-effectiveness of adjuvant immunotherapy with cytokine-induced killer cell for hepatocellular carcinoma based on a randomized controlled trial and real-world data", Front Oncol, 11, pp.728740~ (2021)
  815. Jannin A, "Tyrosine kinase inhibitors and immune checkpoint inhibitorsinduced thyroid disorders", Crit Rev Oncol Hematol, 141, pp.23~35 (2019)
  816. Shimose S, "Clinical significance of adverse events for patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter retrospective study", Cancers(Basel), 12, pp.1867~ (2020)
  817. Sasaki R, "Response to lenvatinib is associated with optimal relativedose intensity in hepatocellular carcinoma:experience in clinical settings", Cancers(Basel), 11, pp.1769~ (2019)
  818. Ohki T, "Impact of adverse events on the progression-free survival of patients with advanced hepatocellular carcinoma treated with lenvatinib : a multicenter retrospective study", Drugs Real World Outcomes, 7, pp.141~149 (2020)
  819. Maruta S, "Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma", Liver Cancer, 9, pp.382~396 (2020)
  820. Sho T, "Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria", Hepatol Res, 50, pp.966~977 (2020)
  821. Goh MJ, "Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea", Liver Cancer, 10, pp.52~62 (2021)
  822. Sho T, "Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting", JGH Open, 4, pp.54~60 (2020)
  823. Cheon J, "Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma : a multicenter retrospective analysis", Liver Cancer, 9, pp.613~624 (2020)
  824. Ogushi K, "Safety and efficacy of lenvatinib treatment in Child-Pugh A and B patients with unresectable hepatocellular carcinoma in clinical practice : a multicenter analysis", Clin Exp Gastroenterol, 13, pp.385~396 (2020)
  825. Sho T, "Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria", Hepatol Res, 51, pp.979~989 (2021)
  826. Hayakawa Y, "Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice", Invest New Drugs, 40, pp.392~402 (2022)
  827. Kelley RK, "Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma : randomized expansion of a phase I", II study, 2021, pp.39, 2991~3001
  828. Abou-Alfa GK, "Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA", J Clin Oncol (2022)
  829. Qin S, "Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma : a randomized, open-label, parallel-controlled phase II-III trial", J Clin Oncol, 39, pp.3002~3011 (2021)
  830. Kelley RK, "VP10-2021 : cabozantinib(C)plus atezolizumab(A)versus sorafenib(S)as first-line systemic treatment for advanced hepatocellular carcinoma(aHCC) : results from the randomized phase III COSMIC-312 trial", Ann Oncol, 33, pp.114~116 (2022)
  831. Cheng AL, "Updated efficacy and safety data from IMbrave150 : atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma", J Hepatol, 76, pp.862~873 (2022)
  832. d’Izarny-Gargas T, "Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer : a systematic review", Am J Transplant, 20, pp.2457~2465 (2020)
  833. Pinter M, "Immunotherapy for advanced hepatocellular carcinoma : a focus on special subgroups", Gut, 70, pp.204~214 (2021)
  834. Rimassa L, "Systemic treatment of HCC in special populations", J Hepatol, 74, pp.931~943 (2021)
  835. Pfister D, "NASH limits anti-tumour surveillance in immunotherapy-treated HCC", Nature, 592, pp.450~456 (2021)
  836. Finn RS, "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
  837. Jackson R, "Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer : a meta-analysis of randomized phase III trials", J Clin Oncol, 35, pp.622~628 (2017)
  838. Reig M, "Postprogression survival of patients with advanced hepatocellular carcinoma : rationale for second-line trial design", Hepatology, 58, pp.2023~2031 (2013)
  839. Lencioni R, "GIDEON(Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) : second interim analysis", Int J Clin Pract, 68, pp.609~617 (2014)
  840. Llovet JM, "Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed : results from the randomized phase III BRISKPS study", J Clin Oncol, 31, pp.3509~3516 (2013)
  841. Zhu AX, "Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib : the EVOLVE-1 randomized clinical trial", JAMA, 312, pp.57~67 (2014)
  842. Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicentre, phase 3 trial", Lancet Oncol, 16, pp.859~870 (2015)
  843. Rimassa L, "Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma(METIVHCC) : a final analysis of a phase 3, randomised, placebocontrolled study", Lancet Oncol, 19, pp.682~693 (2018)
  844. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
  845. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
  846. Qin S, "Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma(HCC) : phase 3 KEYNOTE-394 study", J Clin Oncol (2022)
  847. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations(REACH-2) : a randomised, double-blind, placebocontrolled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
  848. Sonbol MB, "Systemic therapy and sequencing options in advanced hepatocellular carcinoma : a systematic review and network meta-analysis", JAMA Oncol, 6, pp.e204930~ (2020)
  849. Lim H, "Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma : a systematic review", J Natl Cancer Inst, 113, pp.123~136 (2021)
  850. Wilhelm SM, "Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity", Int J Cancer, 129, pp.245~255 (2011)
  851. Abou-Elkacem L, "Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model", Mol Cancer Ther, 12, pp.1322~1331 (2013)
  852. Wilhelm SM, "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF", MEK, Cancer Res, pp.2004, 64[DOI]
  853. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
  854. Kudo M, "CheckMate 040 cohort 5 : a phase I", II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis, 2021, pp.75, 600~609
  855. Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib : the CheckMate 040 randomized clinical trial", JAMA Oncol, 6, pp.e204564~ (2020)
  856. Qin S, "Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma(AHELP) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Gastroenterol Hepatol, 6, pp.559~568 (2021)
  857. Qin S, "Camrelizumab in patients with previously treated advanced hepatocellular carcinoma : a multicentre, open-label, parallel-group, randomised, phase 2 trial", Lancet Oncol, 21, pp.571~580 (2020)
  858. Cheol-Hyung Lee, "Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment", Clinical and Molecular Hepatology, 26(3), pp.328~339 (2020), 대한간학회[DOI]
  859. Choi WM, "Regorafenib versus nivolumab after sorafenib failure : real-world data in patients with hepatocellular carcinoma", Hepatol Commun, 4, pp.1073~1086 (2020)
  860. Alsina A, "Effects of subsequent systemic anticancer medication following first-line lenvatinib : a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma", Liver Cancer, 9, pp.93~104 (2020)
  861. Ando Y, "Analysis of post-progression survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib", Oncology, 98, pp.787~797 (2020)
  862. Koroki K, "Posttreatment after lenvatinib in patients with advanced hepatocellular carcinoma", Liver Cancer, 10, pp.473~484 (2021)
  863. Hiraoka A, "Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma", Gastroenterol Rep(Oxf), 9, pp.133~138 (2020)
  864. Brandi G, "Metronomic capecitabine in advanced hepatocellular carcinoma patients : a phase II study", Oncologist, 18, pp.1256~1257 (2013)
  865. Mir O, "Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pretreated with sorafenib", Med Oncol, 29, pp.2793~2799 (2012)
  866. Lee JE, "Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenibrefractory metastatic hepatocellular carcinoma", World J Gastroenterol, 20, pp.235~241 (2014)
  867. Thomas MB, "Systemic therapy for hepatocellular carcinoma", Cancer J, 14, pp.123~127 (2008)
  868. Petrelli F, "Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis", Clin Oncol(R Coll Radiol), 26, pp.488~496 (2014)
  869. Qin S, "Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil", leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia, 2013, pp.31, 3501~3508
  870. Patrikidou A, "Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of antiangiogenic therapies", Invest New Drugs, 32, pp.1028~1035 (2014)
  871. 임태영, "비대상성 간경변을 동반한 진행성 간세포암종에서 간동맥내 저용량 5-fluorouracil 및 cisplatin 주입요법의 효과", Clinical and Molecular Hepatology, 12(2006), pp.65~73 (2006), 대한간학회
  872. Woo HY, "A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma", Cancer Chemother Pharmacol, 65, pp.373~382 (2010)
  873. Hamada A, "Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma : prognostic factors", J Vasc Interv Radiol, 15, pp.835~841 (2004)
  874. Ueshima K, "Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma", Oncology, 78(Suppl 1), pp.148~153 (2010)
  875. Kudo M, "Survival analysis over 28 years of 173, 378patients with hepatocellular carcinoma in Japan", Liver Cancer, 5, pp.190~197 (2016)
  876. Kawaoka T, "Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma", J Dig Dis, 16, pp.505~512 (2015)
  877. Terashima T, "Beneficial effect of maintaining hepatic reserve during chemotherapy on the outcomes of patients with hepatocellular carcinoma", Liver Cancer, 6, pp.236~249 (2017)
  878. Terashima T, "Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib", Hepatol Res, 44, pp.1179~1185 (2014)
  879. Jeong SW, "The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma", Asia Pac J Clin Oncol, 8, pp.164~171 (2012)
  880. Song DS, "A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis", J Gastroenterol, 50, pp.445~454 (2015)
  881. Fukubayashi K, "Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma : a comparative study using the propensity score matching method", Cancer Med, 4, pp.1214~1223 (2015)
  882. Choi JH, "Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis", Cancer Chemother Pharmacol, 82, pp.469~478 (2018)
  883. Lyu N, "Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma : a biomolecular exploratory, randomized, phase III trial(FOHAIC-1)", J Clin Oncol, 40, pp.468~480 (2022)
  884. Lee J, "Comparative analysis of lenvatinib and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma : a multi-center, propensity score study", J Clin Med, 10, pp.4045~ (2021)
  885. Ikeda M, "Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma : randomized phase II trial", Ann Oncol, 27, pp.2090~2096 (2016)
  886. Kudo M, "Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS) : a randomised, open label, phase 3 trial", Lancet Gastroenterol Hepatol, 3, pp.424~432 (2018)
  887. Kondo M, "Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma : SCOOP-2 trial", BMC Cancer, 19, pp.954~ (2019)
  888. He M, "Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion : a randomized clinical trial", JAMA Oncol, 5, pp.953~960 (2019)
  889. Zheng K, "Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis : a randomized trial", Radiology, 303, pp.455~464 (2022)
  890. Chen S, "Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining : a multicenter retrospective study", BMC Cancer, 21, pp.1126~ (2021)
  891. He MK, "Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma", Ther Adv Med Oncol, 13, pp.17588359211002720~ (2021)
  892. Li QJ, "Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma : a randomized phase III trial", J Clin Oncol, 40, pp.150~160 (2022)
  893. Park JW, "Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma : the phase III STAH trial", J Hepatol, 70, pp.684~691 (2019)
  894. Zhenwei Peng, "Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)", Journal of Clinical Oncology, 41(1), pp.117~127 (2023), American Society of Clinical Oncology (ASCO)[DOI]
  895. Robert C, "Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma", J Clin Oncol, 36, pp.1668~1674 (2018)
  896. Jansen YJL, "Discontinuation of anti-PD-1antibody therapy in the absence of disease progression or treatment limiting toxicity : clinical outcomes in advanced melanoma", Ann Oncol, 30, pp.1154~1161 (2019)
  897. Roayaie S, "A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma", Gastroenterology, 137, pp.850~855 (2009)
  898. Belghiti J, "Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis", Ann Surg, 214, pp.114~117 (1991)
  899. Liao M, "Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma : a meta-analysis", Scand J Gastroenterol, 52, pp.624~634 (2017)
  900. Hong Y, "Adjuvant intrahepatic injection iodine-131-lipiodol improves prognosis of patients with hepatocellular carcinoma after resection : a meta-analysis", Indian J Surg, 77(Suppl 3), pp.1227~1232 (2015)
  901. Riaz IB, "Role of vitamin K2 in preventing the recurrence of hepatocellular carcinoma after curative treatment : a meta-analysis of randomized controlled trials", BMC Gastroenterol, 12, pp.170~ (2012)
  902. Chu KJ, "Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis", Asian J Surg, 33, pp.120~126 (2010)
  903. Zhong J, "Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma : a systematic review", Mol Clin Oncol, 2, pp.1091~1096 (2014)
  904. Bruix J, "Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM) : a phase 3, randomised, double-blind, placebo-controlled trial", Lancet Oncol, 16, pp.1344~1354 (2015)
  905. Zhu XD, "Adjuvant therapies after curative treatments for hepatocellular carcinoma : current status and prospects", Genes Dis, 7, pp.359~369 (2020)
  906. Takayama T, "Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma : a randomised trial", Lancet, 356, pp.802~807 (2000)
  907. Xu L, "A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma", Oncoimmunology, 5, pp.e1083671~ (2016)
  908. Lee JH, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma", Gastroenterology, 148, pp.1383~1391 (2015)
  909. Yu X, "A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma", J Clin Immunol, 34, pp.194~203 (2014)
  910. Hui D, "A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma", Dig Liver Dis, 41, pp.36~41 (2009)
  911. Weng DS, "Minimally invasive treatment combined with cytokineinduced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas", J Immunother, 31, pp.63~71 (2008)
  912. Lee JH, "Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma : an extended 5-year follow-up", Cancer Immunol Immunother, 68, pp.23~32 (2019)
  913. Yoon JS, "Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma : a propensity score-matched analysis of real-world data", BMC Cancer, 19, pp.523~ (2019)
  914. Wang H, "Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis", Dig Liver Dis, 48, pp.1275~1282 (2016)
  915. Yeo W, "Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy", Ann Oncol, 15, pp.1661~1666 (2004)
  916. Nagamatsu H, "Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy", Am J Gastroenterol, 99, pp.2369~2375 (2004)
  917. Jang JW, "Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma", PLoS One, 10, pp.e0122041~ (2015)
  918. Lim S, "Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib", J Gastroenterol Hepatol, 30, pp.1024~1031 (2015)
  919. Lee PC, "Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma", J Immunother Cancer, 8, pp.e001072~ (2020)
  920. Park JW, "Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma : report of a prospective study", Am J Gastroenterol, 100, pp.2194~2200 (2005)
  921. Lao XM, "Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma", Liver Int, 33, pp.595~604 (2013)
  922. Lao XM, "Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma", Hepatol Res, 41, pp.553~563 (2011)
  923. Jang JW, "A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization", Hepatology, 43, pp.233~240 (2006)
  924. Xu X, "Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma", J Gastroenterol Hepatol, 29, pp.1273~1278 (2014)
  925. Li X, "Efficacy of prophylactic entecavir for hepatitis B virus-related hepatocellular carcinoma receiving transcatheter arterial chemoembolization", Asian Pac J Cancer Prev, 16, pp.8665~8670 (2015)
  926. Jang JW, "Association of prophylactic anti-hepatitis B virus therapy with improved long-term survival in patients with hepatocellular carcinoma undergoing transarterial therapy", Clin Infect Dis, 71, pp.546~555 (2020)
  927. Tamori A, "Lamivudine therapy for hepatitis B virus reactivation in a patient receiving intra-arterial chemotherapy for advanced hepatocellular carcinoma", Hepatol Res, 26, pp.77~80 (2003)
  928. Liu S, "Effects of antiviral therapy on HBV reactivation and survival in hepatocellular carcinoma patients undergoing hepatic artery infusion chemotherapy", Front Oncol, 10, pp.582504~ (2020)
  929. Kubo S, "Reactivation of viral replication after liver resection in patients infected with hepatitis B virus", Ann Surg, 233, pp.139~145 (2001)
  930. Huang L, "Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy : a randomized controlled trial", J Viral Hepat, 20, pp.336~342 (2013)
  931. Huang G, "Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma : a randomized controlled trial", Ann Surg, 261, pp.56~66 (2015)
  932. Kim JH, "Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 69, pp.813~819 (2007)
  933. Jang JW, "Risk of HBV reactivation according to viral status and treatment intensity in patients with hepatocellular carcinoma", Antivir Ther, 16, pp.969~977 (2011)
  934. Jun BG, "Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment : a multicenter study", PLoS One, 13, pp.e0201316~ (2018)
  935. Dan JQ, "Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma : a retrospective study", Eur J Surg Oncol, 39, pp.865~872 (2013)
  936. Yoshida H, "Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma", Hepatol Int, 2, pp.89~94 (2008)
  937. Lee JI, "Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus", J Gastroenterol Hepatol, 29, pp.1019~1027 (2014)
  938. Chang JI, "Clinical outcomes of hepatitis B virus-related hepatocellular carcinoma patients with undetectable serum HBV DNA levels", Dig Dis Sci, 67, pp.4565~4573 (2022)
  939. Papatheodoridi M, "Risk of HBV reactivation during therapies for HCC : a systematic review", Hepatology, 75, pp.1257~1274 (2022)
  940. 성필수, "Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization", Clinical and Molecular Hepatology, 17(4), pp.299~306 (2011), 대한간학회
  941. Carr BI, "Pain at presentation and survival in hepatocellular carcinoma", J Pain, 11, pp.988~993 (2010)
  942. Ibrahim NM, "Effect of transcranial direct current stimulation of the motor cortex on visceral pain in patients with hepatocellular carcinoma", Pain Med, 19, pp.550~560 (2018)
  943. Chwistek M, "Recent advances in understanding and managing cancer pain", F1000Res, 6, pp.945~ (2017)
  944. Hong SH, "Change in cancer pain management in Korea between 2001and 2006 : results of two nationwide surveys", J Pain Symptom Manage, 41, pp.93~103 (2011)
  945. Kim JY, "Prevalence and management of pain by different age groups of Korean cancer patients", Am J Hosp Palliat Care, 30, pp.393~398 (2013)
  946. van den Beuken-van Everdingen MH, "Prevalence of pain in patients with cancer : a systematic review of the past 40 years", Ann Oncol, 18, pp.1437~1449 (2007)
  947. Grudzen CR, "Emergency department-initiated palliative care in advanced cancer : a randomized clinical trial", JAMA Oncol, 2, pp.591~598 (2016)
  948. Bakitas MA, "Early versus delayed initiation of concurrent palliative oncology care : patient outcomes in the ENABLE III randomized controlled trial", J Clin Oncol, 33, pp.1438~1445 (2015)
  949. Zimmermann C, "Early palliative care for patients with advanced cancer : a cluster-randomised controlled trial", Lancet, 383, pp.1721~1730 (2014)
  950. Temel JS, "Early palliative care for patients with metastatic non-small-cell lung cancer", N Engl J Med, 363, pp.733~742 (2010)
  951. Ryu E, "Symptom clusters and quality of life in Korean patients with hepatocellular carcinoma", Cancer Nurs, 33, pp.3~10 (2010)
  952. Verbeeck RK, "Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction", Eur J Clin Pharmacol, 64, pp.1147~1161 (2008)
  953. Radner H, "Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity", Cochrane Database Syst Rev (2012)
  954. World Health Organization(WHO), "Cancer pain relief : with a guide to opioid availability" (1996), WHO
  955. Ministry of Health & Welfare, "Cancer pain management guideline", Ministry of Health & Welfare, ~ (2012)
  956. National Comprehensive Cancer Network (NCCN), "NCCN clinical practice guideline in oncology: adult cancer pain", NCCN, 1 (2013)
  957. Rossi S, "Use of over-the-counter analgesics in patients with chronic liver disease : physicians’ recommendations", Drug Saf, 31, pp.261~270 (2008)
  958. Larson AM, "Acetaminophen-induced acute liver failure : results of a United States multicenter, prospective study", Hepatology, 42, pp.1364~1372 (2005)
  959. UFaDAF UDoHaHS, "Drugs: acetaminophen information", US Department of Health and Human Services, ~ (2017)
  960. Mofredj A, "Hepatotoxicity caused by therapeutic doses of paracetamol in alcoholics. Report of 2 cases of fatal hepatitis in cirrhosis", Ann Med Interne(Paris), 150, pp.507~511 (1999)
  961. Dart RC, "Does therapeutic use of acetaminophen cause acute liver failure?", Pharmacotherapy, 27, pp.1219~1230 (2007)
  962. Kuffner EK, "The effect of acetaminophen(four grams a day for three consecutive days)on hepatic tests in alcoholic patients--a multicenter randomized study", BMC Med, 5, pp.13~ (2007)
  963. Heard K, "A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol(acetaminophen)administration in subjects who consume moderate amounts of alcohol", Aliment Pharmacol Ther, 26, pp.283~290 (2007)
  964. Khalid SK, "Use of over-thecounter analgesics is not associated with acute decompensation in patients with cirrhosis", Clin Gastroenterol Hepatol, 7, pp.994~999 (2009)
  965. Villeneuve JP, "Pharmacokinetics and metabolism of acetaminophen in normal, alcoholic and cirrhotic subjects", Gastroenterol Clin Biol, 7, pp.898~902 (1983)
  966. Hirschfield GM, "Preventative hepatology : minimising symptoms and optimising care", Liver Int, 28, pp.922~934 (2008)
  967. Benson GD, "The therapeutic use of acetaminophen in patients with liver disease", Am J Ther, 12, pp.133~141 (2005)
  968. Chandok N, "Pain management in the cirrhotic patient : the clinical challenge", Mayo Clin Proc, 85, pp.451~458 (2010)
  969. Williams RL, "Naproxen disposition in patients with alcoholic cirrhosis", Eur J Clin Pharmacol, 27, pp.291~296 (1984)
  970. Bessone F, "Non-steroidal anti-inflammatory drugs : what is the actual risk of liver damage?", World J Gastroenterol, 16, pp.5651~5561 (2010)
  971. Riley TR 3rd, "Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C : a case series", Am J Gastroenterol, 93, pp.1563~1565 (1998)
  972. Ackerman Z, "Effect of misoprostol on ibuprofen-induced renal dysfunction in patients with decompensated cirrhosis : results of a double-blind placebo-controlled parallel group study", Am J Gastroenterol, 97, pp.2033~2039 (2002)
  973. Castro-Fernández M, "Influence of nonsteroidal antiinflammatory drugs in gastrointestinal bleeding due to gastroduodenal ulcers or erosions in patients with liver cirrhosis", Gastroenterol Hepatol, 29, pp.11~14 (2006)
  974. Lee YC, "Nonsteroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients", Liver Int, 32, pp.859~866 (2012)
  975. Kotb HI, "Pharmacokinetics of oral tramadol in patients with liver cancer", J Opioid Manag, 4, pp.99~104 (2008)
  976. Christian-Miller N, "Hepatocellular cancer pain : impact and management challenges", J Hepatocell Carcinoma, 5, pp.75~80 (2018)
  977. Smith HS, "Opioid metabolism", Mayo Clin Proc, 84, pp.613~624 (2009)
  978. Hasselström J, "The metabolism and bioavailability of morphine in patients with severe liver cirrhosis", Br J Clin Pharmacol, 29, pp.289~297 (1990)
  979. Tegeder I, "Pharmacokinetics of opioids in liver disease", Clin Pharmacokinet, 37, pp.17~40 (1999)
  980. Kotb HI, "Pharmacokinetics of controlled release morphine(MST)in patients with liver carcinoma", Br J Anaesth, 94, pp.95~99 (2005)
  981. Tallgren M, "Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation", Clin Pharmacol Ther, 61, pp.655~661 (1997)
  982. Durnin C, "Pharmacokinetics of oral immediate-release hydromorphone(Dilaudid IR)in subjects with moderate hepatic impairment", Proc West Pharmacol Soc, 44, pp.83~84 (2001)
  983. Haberer JP, "Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis", Br J Anaesth, 54, pp.1267~1270 (1982)
  984. Berry P, "Improving end of life care in liver disease", J Hepatol, 76, pp.1225~1226 (2022)
  985. Kashima M, "Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma", AJR Am J Roentgenol, 194, pp.536~541 (2010)
  986. Nagata Y, "Osseous metastases from hepatocellular carcinoma : embolization for pain control", Cardiovasc Intervent Radiol, 12, pp.149~153 (1989)
  987. Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
  988. Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
  989. Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
  990. Lencioni R, "Modified RECIST(mRECIST)assessment for hepatocellular carcinoma", Semin Liver Dis, 30, pp.52~60 (2010)
  991. Forner A, "Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma : are response evaluation criteria in solid tumors reliable?", Cancer, 115, pp.616~623 (2009)
  992. Bruix J, "Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver", J Hepatol, 35, pp.421~430 (2001)
  993. Llovet JM, "Design and endpoints of clinical trials in hepatocellular carcinoma", J Natl Cancer Inst, 100, pp.698~711 (2008)
  994. Chiou VL, "Pseudoprogression and immunerelated response in solid tumors", J Clin Oncol, 33, pp.3541~3543 (2015)
  995. Jia W, "The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy", Cancer Biol Med, 16, pp.655~670 (2019)
  996. Lee DH, "Outcome of initial progression during nivolumab treatment for hepatocellular carcinoma: should we use iRECIST?", Front Med (Lausanne), 8, pp.771887~ (2021)
  997. Lewis S, "Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC", Abdom Radiol(NY), 47, pp.969~980 (2022)
  998. Seymour L, "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", Lancet Oncol, 18, pp.e143~e152 (2017)
  999. Llovet JM, "mRECIST for HCC : performance and novel refinements", J Hepatol, 72, pp.288~306 (2020)
  1000. Anil Arora, "Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma", Journal of Clinical and Experimental Hepatology, 4, pp.S126~S129 (2014), Elsevier BV[DOI]
  1001. Lencioni R, "Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC", J Hepatol, 66, pp.1166~1172 (2017)
  1002. Llovet JM, "Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of surviva", J Hepatol, 70, pp.1262~1277 (2019)
  1003. Yamamoto K, "AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC", J Gastroenterol, 45, pp.1272~1282 (2010)
  1004. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
  1005. Llovet JM, "Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference", Hepatology, 73(1), pp.158~191 (2021)
  1006. Hodi FS, "Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy", J Clin Oncol, 36, pp.850~858 (2018)
  1007. Tazdait M, "Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, ir- RECIST and iRECIST criteria", Eur J Cancer, 88, pp.38~47 (2018)
  1008. Poon RT, "Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies", Ann Surg Oncol, 16, pp.792~794 (2009)
  1009. Liu D, "Evidence-based surveillance imaging schedule after liver transplantation for hepatocellular carcinoma recurrence", Transplantation, 101, pp.107~111 (2017)
  1010. Tanaka K, "Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection", World J Surg, 32, pp.1738~1747 (2008)
  1011. Hyder O, "Trends and patterns of utilization in posttreatment surveillance imaging among patients treated for hepatocellular carcinoma", J Gastrointest Surg, 17, pp.1774~1783 (2013)
  1012. Zheng J, "Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort", Ann Surg, 266, pp.693~701 (2017)
  1013. Dioguardi Burgio M, "Follow-up imaging after liver transplantation should take into consideration primary hepatocellular carcinoma characteristics", Transplantation, 99, pp.1613~1618 (2015)
  1014. Kovalic AJ, "Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis", Hepatol Int, 14, pp.612~620 (2020)
  1015. Yang H, "Chronic liver disease independently associated with COVID-19 severity: evidence based on adjusted effect estimates", Hepatol Int, 15, pp.217~222 (2021)
  1016. Mallet V, "Demosthenes research group. Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020", J Hepatol, 75, pp.848~855 (2021)
  1017. Kim D, "Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study", Clin Gastroenterol Hepatol, 19, pp.1469~1479 (2021)
  1018. Polack FP, "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
  1019. Baden LR, "Baden LR, El Sahly HM, Essink B, KotloffK, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
  1020. Oliver SE, "Use of the Janssen (Johnson & Johnson) COVID-19 vaccine: updated interim recommendations from the advisory committee on immunization practices - United States, December 2021", MMWR Morb Mortal Wkly Rep, 71, pp.90~95 (2022)
  1021. Gargano JW, "Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, June 2021", MMWR Morb Mortal Wkly Rep, 70, pp.977~982 (2021)
  1022. National Comprehensive Cancer Network (NCCN), "NCCN: cancer and COVID-19 vaccination version 7.0", Plymouth Meeting: NCCN, ~ (2022)
  1023. Waissengrin B, "Shortterm safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors", Lancet Oncol, 22, pp.581~583 (2021)
  1024. Blumenthal KG, "Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2", N Engl J Med, 384, pp.1273~1277 (2021)
  1025. Bril F, "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?", J Hepatol, 75, pp.222~224 (2021)
  1026. McShane C, "The mRNA COVID-19 vaccine - a rare trigger of autoimmune hepatitis?", J Hepatol, 75, pp.1252~1254 (2021)
  1027. Wang Y, "Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China", BMJ Glob Health, 5, pp.e002794~ (2020)
  1028. Brooks JT, "Effectiveness of mask wearing to control community spread of SARS-CoV-2", JAMA, 325, pp.998~999 (2021)

관련 논문AI추천

2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular CarcinomaKorean Liver Cancer Association (KLCA) and National Cancer Center (NCC거트앤리버 소화기연관학회협의회 · Gut and Liver2019 · 제13권 제3호Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspectiveDong Ho Hyun, Dong Hyun Sinn, Jeong Il Yu, Jong Man Kim, Jung Yong Hong, Min Woo Lee, Moon Seok Choi, Myung Ji Goh대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma한국 간 암 스터디그룹, 국립 암 센터거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제3호Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparisonBo Hyun Kim, Joong-Won Park, Yuri Cho대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Hong Kong perspectiveLung-Yi Mak, Man-Fung Yuen, Rex Wan-Hin Hui, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspectiveCheng-Maw Ho, Chih-Horng Wu, Chun-Jen Liu, Tsung-Hao Liu, Tung-Hung Su대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호

이 간행물의 다른 논문 (24건)

The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathologyJong-Hoon Kim, Youngseok Leepp. 706-724Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative reviewGiovanni Targher, Ming-Hua Zheng, Jing Xu, Lei Miao, Christopher D Byrnepp. 725-738Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive reviewJong Man Kim, Sang Jin Kimpp. 739-753Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncologyHyun-Jong Jang, Sung Hak Leepp. 754-772Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseasesHwang Sik Shin, Sang-Wook Yi, Baek Gyu Junpp. 773-789
원문 보기